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ABSTRACT 
 
CRYPTOPHANE DERIVATIVES AS GAS SENSORS AND HYPERPOLARIZED 
XENON-129 BIOSENSORS  
 
Najat S. Khan 
 
Professor Ivan J. Dmochowski 
 
 
This thesis describes the progress in the development of cryptophanes for three 
different applications: encapsulation of noble gases, 129Xe NMR biosensing for cancer 
detection, and the construction of molecular devices. A new water-soluble organic host 
molecule, tris-(triazole ethylamine) cryptophane, was synthesized for noble gas detection. 
This host was found to bind xenon with the highest affinity to date (KA = 42,000 ± 2,000 
M-1 at 293 K). The same host was employed in the development of a radiometric assay 
for measuring the association constant of radon binding to a discrete molecular species, 
KA = 49,000 ± 12,000 M-1 at 293 K. For cancer detection by hyperpolarized 129Xe MRI, a 
new folate-conjugated cryptophane biosensor was developed that targets folate receptors 
(FR) overexpressed in a majority of cancer cells. The biosensor was relatively non-toxic 
at low micromolar concentrations required for imaging and was shown to selectively 
target cancer cells overexpressing FR. Flow cytometry results indicated a 10-fold higher 
cellular internalization in KB cells (FR+) than in HT-1080 cells (FR-). Finally, a smaller 
cavity tribenzylamine hemicryptophane was synthesized where the molecular structure 
and motions of the cage closely resembled that of molecular gyroscopes. It also provided 
a vehicle for exploring the structure and properties of multiple p-phenylene rotators 
 viii 
within one molecule. The compact size and molecular motions of this gyroscope-inspired 
tribenzylamine hemicryptophane make it an attractive starting point for controlling the 
direction and coupling of rotators within molecular systems. 
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CHAPTER 1: INTRODUCTION 
1.1.   The role of cryptophanes in host-guest chemistry 
 
Host-guest chemistry involves the encapsulation of neutral and charged species by 
a variety of synthetic molecular systems.1 This host-guest association is a key aspect of 
many applications in chemistry and biochemistry and has helped to elucidate many of the 
fundamentals of molecular recognition2-9 and complexation among biological systems in 
Nature.10-16 One of the first model studies of molecular recognition involved the binding 
of ammonium ions by crown ethers in solution by Pederson et al.17 Since then, there has 
been a rapid growth in the synthesis of various organic hosts and investigation of their 
binding to guest molecules. Examples of organic synthetic host molecules include 
calixarenes,18-22 cavitands,23 cyclodextrins,24,25 crown ethers,24,25 carcerands,26 and 
cryptophanes.1 Due to the different molecular structures of these hosts, a wide variety of 
cavities with guest-binding properties are present, which has led to applications in drug 
delivery,27 molecular recognition,23 storage and separation,28 and catalysis.29-31 
 
Cryptophane-A is a molecular cage that was first developed by André Collet in 
1981.32,33 Since then, extensive research has been performed with this cage and its 
derivatives in the field of host-guest chemistry.1 It is a chiral molecule with D3 symmetry, 
which is formed when two CTV (cyclotriveratrylene) units are joined by three ethylene 
linkers (Figure 1.1). Guests are encapsulated within the cavity due to the presence of the 
three portals in the equatorial region of the cage. Previous work has shown that the size 
 2 
and nature of the cavity can be tuned by varying the molecular structure as well as the 
length of the linkers.34 The internal volume has been estimated to be 87 Å3 (Figure 1.1), 
based on high-resolution X-ray crystallographic studies.35,36 Cryptophane-A has been 
shown to reversibly bind to a variety of neutral small molecules (e.g. methane, KA = 130 
M-1 in C2D2Cl4 at 298 K; chloroform, KA = 230 M-1 in C2D2Cl4 at 298 K; and xenon, KA 
= 3900 M-1 in C2D2Cl4 at 278 K).37,38  
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Figure 1.1. Cryptophane-A consists of two CTV units, which are joined by three 
ethylene linkers to give an internal volume of 87 Å3. 
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Figure 1.1. Structure of Cryptophane-A.  
Cryptophane-A consists of two cyclotriveratrylene caps joined by ethylene ether 
bridges. Cryptophane-A has a diameter of 1 nm and an internal volume of 
approximately 95 Å3. 
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High-resolution X-ray structures of cryptophane-A and trifunctionalized derivative 
complexes have been reported with water, methanol, xenon and chloroform in the 
Dmochowski group.36 In the case of methanol and xenon, the cavity is underfilled with a 
packing coefficient (defined as guest volume divided by host internal volume) of 0.39 
and 0.47 respectively, whereas it is overfilled with chloroform as the guest (0.73).36 
According to Rebek’s “55% rule”, the volume of the guest and host are both critical for 
encapsulation processes to occur. By studying a variety of host-guest complexes they 
were able to determine that optimal binding is reached when the packing coefficient is 
0.55 ± 0.09 in organic liquids.35 It is therefore not surprising that xenon binds with the 
highest affinity to cryptophane since the packing coefficient at 0.47 is closest to the 
empirically determined value reported by Rebek et al. This is also supported by the fact 
that X-ray structures indicated nearly optimized van der Waals interactions between 
xenon and the six cyclotriguaiacylene (CTG) phenyl moieties (experimental average = 
4.31 Å, optimal van der Waals interaction distance for Xe and phenyl carbon is 3.86 Å).36 
In order to accommodate guests of different sizes, the crystal structures indicate that the 
trifunctionalized cryptophanes are able to increase the internal cavity volume by more 
than 20% by the expansion of two of the three ethylene linkers (Figure 1.2).36 This study 
provided the first example of xenon-cryptophane association in the solid state and further 
demonstrated the role of cryptophanes as organic hosts that are capable of undergoing 
‘induced fit’ to optimize binding via London forces to guest molecules. 
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Figure 1.2. Side view of two superimposed crystal structures of a cryptophane-A 
derivative, triallyl cryptophane. The cryptophane is shown encapsulating MeOH (grey) 
and CDCl3 (pink). Guests, hydrogens and side chains were removed for easier viewing. 
Figure adapted from Taratula et al.36 
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In order to eventually perform in vivo studies, water-soluble versions of 
cryptophane-A have also been synthesized: Huber’s hexa-acid cryptophanes (KA = 6,800 
M-1 at 293 K) where the six methoxy groups were replaced by -OCH2CO2H groups,39 
tris-(triazole propionic acid) cryptophane (TTPC) (KA = 17,000 M-1 at 293 K),40 and 
triacetate-functionalized cryptophane (TAAC) (KA = 33,000 M-1 at 293 K) (Figure 1.3).41 
The binding of xenon to TTPC and TAAC was measured by isothermal titration 
calorimetry (ITC) and fluorescence quenching.40,41 TAAC has three carboxylate groups 
close to the cryptophane core and was determined to have the highest binding affinity for 
xenon of any host molecule in buffer.41 The higher binding affinity in aqueous buffer 
compared to organic solvents is due to the higher enthalpic and entropic contributions in 
buffer. The higher enthalpic contributions arise from increased van der Waals interactions 
due to a more compact shape in water (assisted by the flexible ethylene linkers) whereas 
the desolvation of the water shell around xenon upon binding to cryptophane accounts for 
the high entropic contribution (Figure 1.3).40,41 
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Figure 1.3. Water-soluble cryptophanes a) Huber’s hexa-acid cryptophanes, b) TAAC 
and TTPC, c) A major contributor to xenon binding is entropy which arises from the 
desolvation of Xe. Roughly 20 water molecules make up the first solvation sphere of the 
Xe atom in aqueous solution. Figure adapted from Huber and Hill, et al.39-41 
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Figure 1.2. Huber’s Hexa-acid Cryptophanes.  
A.) Huber et al. synthesized a series of water-soluble cryptophanes that differed 
in the length of the dioxy alkane bridges. B.) Chemical shifts m ved upfield 
about 30 ppm with increasing cavity size from about 65 ppm for the smallest 
cryptophane to about 35 ppm for the largest cryptophane. Figure adapted from 
Huber et al.35 
A 
B 
!
a)! b)!
c)!
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This thesis outlines the synthesis and development of a new water-soluble amine-
based cryptophane-A derivative with the goals of expanding the variety of neutral 
molecules reversibly binding to cryptophanes and determining the substituent effects on 
xenon binding affinity. The binding of radon and xenon to this molecule was 
investigated. Although both radon and xenon are noble gases, unlike xenon, all 35 
isotopes of radon are radioactive. Radon is formed as an intermediate species resulting 
from the decay of uranium-238, which is found in the Earth’s crust. It is considered to be 
an indoor air pollutant since exposure to radon (due to high levels of accumulation within 
homes) leads to the incidence of lung cancers in many geographic regions.42 Despite this, 
there is currently no literature data for the binding of radon to a discrete molecular 
species. So far, only the adsorption of radon to bulk substrates such as charcoal, silica gel 
and ice,43 and on the formation of radon halides44 has been determined. Therefore, a 
novel sensitive assay was developed in the Dmochowski lab to determine the binding of 
radon to cryptophane. Additionally, the binding of xenon to the same host was also 
investigated using isothermal titration calorimetry (ITC). 
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1.2. Development of targeted 129Xe biosensors 
 
Among the small, neutral molecules that are reversibly encapsulated by 
cryptophanes, xenon has garnered the most attention. This is because of the promising 
potential of using hyperpolarized (hp) 129Xe biosensors as novel contrast agents for 
magnetic resonance imaging (MRI) and spectroscopy (MRS).45 Although MRI is one of 
the most widely used non-invasive tools for imaging deep tissues with high spatial and 
temporal resolution (with approximately 30 million procedures performed per year in the 
U.S.), it suffers from several limitations. Because the intrinsic signals are from protons in 
water and fat, there is usually low sensitivity and high background noise present. Lungs 
are difficult to image due to low proton concentration whereas in the brain, multiple lipid 
bilayers decrease sensitivity due to high proton noise, resulting in poor signal-to-noise 
ratios.46,47 As a result, several small tumors may remain undetected until they have 
progressed and become larger, which then may hurt patient prognosis. To overcome this 
problem, MRI contrast agents are currently used to increase the signal-to-noise ratio and 
include gadolinium chelates,48-50 iron oxide nanoparticles51-54 and manganese chelates.55 
Contrast agents are generally paramagnetic species that increase signal-to-noise ratio by 
changing the longitudinal (T1) or transverse (T2) relaxation times of neighboring water 
molecules. Gadolinium contrast agents (e.g. Omniscan) are most frequently used and 
account for 40-50% of MRI scans.49 Although they do improve the contrast of MRI 
images, they are not targeted towards specific biomarkers. Since they depend on relative 
changes for imaging, Gd contrast agents are less effective at multiplexing and detecting 
proteins at low concentrations.56,57 Additionally, U.S. and European agencies have issued 
 10 
advisories against Gd agents based on the toxicity risks posed to patients with impaired 
renal function who may develop nephrogenic systemic ﬁbrosis/nephrogenic ﬁbrosing 
dermopathy (NSF/NFD).58 This disease has recently “disappeared”, due to greater 
awareness of NSF and the risks posed to the dialysis                                                                                                                                                                                                                                                                                                                 
patient population. Other contrast agents include iron oxide nanoparticles, which are 
effective at imaging liver lesions, but are plagued by low sensitivity due to small changes 
in T2.54 Manganese chelates are also used but tend to accumulate in the liver and  have 
low sensitivity due to small changes in T1.55 As a result of low sensitivity and toxicity 
concerns, alternative nonproton-based, hyperpolarized MRI agents such as 129Xe, 13C, 
83Kr and 3He are currently being explored.59-62 
 
129Xe is an attractive MRI contrast agent since it is spin-½ (26.5% isotopic 
abundance), non-toxic, inert (below its anesthetic threshold, which is 70% by volume of 
inhaled gas mixtures), has millimolar solubility (~5 mM) in water63 and is very 
polarizable. The polarizability of the 56 electron cloud is reflected by the large chemical 
shift window (> 300 ppm).64 This allows for the simultaneous detection of different 
species (i.e., multiplexing), which is currently not possible with untargeted 1H MRI 
contrast agents. Since most diseases lead to overexpression of a variety of biomarkers, 
the ability to perform multiplexed detection through MRI would greatly increase the 
effectiveness and sensitivity of this imaging modality. Additionally, hp 129Xe can be 
generated through spin-exchange optical pumping (SEOP) to increase NMR signal by 
more than 10,000-fold. This helps to increase the sensitivity of MRI.65 SEOP polarizes 
129Xe gas by transferring angular momentum from circularly polarized light to rubidium. 
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The nuclear spin from polarized rubidium is then transferred to the nuclear spin of xenon 
through dipolar coupling (Figure 1.4a). As a result, a > 10,000-fold signal enhancement is 
achieved relative to the normal Boltzmann distribution of nuclear spins.65,66 The 
hyperpolarized state has a spin–lattice relaxation time T1 of roughly 70 min.67 However, 
the T1 value is significantly reduced in the present of paramagnetic species such as iron 
and oxygen. As a result, the T1 value is only 4 seconds in deoxygenated blood and 13 
seconds in oxygenated blood.68 Despite this, several in vivo MRI imaging studies with hp 
129Xe gas have already been performed. In cases where 129Xe gas was introduced via 
inhalation, organs such as the brain and lungs were successfully imaged.47,69-76 It has also 
been possible to image organs by introducing 129Xe via direct intravenous77 and arterial71 
routes in rodents.  Additionally, since it is now possible to deliver over 50% hp 129Xe at 
ﬂow rates of 1–2 L/min, the potential for performing MRI where hp 129Xe gas is 
continuously replenished via inhalation has further increased.78,79 This would allow for 
organs such as the brain and the lungs to be imaged over extended periods of time. It has 
also been reported that the hyperpolarized lifetime of xenon can be increased to 20-30 
seconds by co-injecting with intralipids or emulsions, which may allow for the possibility 
to image a wider variety of organs.71,80 
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Figure 1.4. a) The process of spin-exchange optical pumping to produce hp 129Xe gas, b) 
Schematic representation illustrating the primary concept of 129Xe NMR biosensing 
whereby there is a distinct shift in 129Xe NMR resonance upon binding to the targeted 
biomarker. Adapted from Taratula et al.45 
 
 
 
 
 
 
 
 
Owing to its filled valence electron shell, xenon resists
forming covalent bonds; nonetheless, it shows modest
affinity for hydrophobic cavities found in many organic
molecules [16–19]. For example, the association con-
stant, KA, is 200 M
!1 for hemicarcerands [20] and
20 M!1 for a-cyclodextrin [17]. A calix[4]arene deriva-
tive exhibited a KA of only "14 M!1 at 298 K in water
[21] whereas for water-soluble cucurbit[6]uril, a xenon
binding constant of 3000 M!1 was measured [18]. In
fact, the non-covalent, dynamic association of 129Xe
with these host molecules creates opportunities for
xenon biosensing applications, as xenon can be hyper-
polarized separately as the gas and subsequently intro-
duced to the host molecule, at multiple time points for
longitudinal studies.
Cryptophane-A, first reported in 1981 [22], is the most
studied Xe-binding cage and is composed of two cyclo-
triveratrylene caps joined by three ethyl linkers, which
give an internal van der Waals volume of approximately
95 A˚
´ 3 (Figure 2). As a result of its connectivity, crypto-
phane-A has D3 symmetry and is chiral. Cryptophane-A is
also commonly referred to as cryptophane-2,2,2, based on
the three 2-carbon spacers. Cryptophane-A binds Xe
reversibly with KA "3900 M!1 in C2D2Cl4 at 278 K
[23]. In a series of related cryptophanes incorporating
3-carbon spacers, xenon affinity decreases with increasing
size of the cavity [24].
Cryptophane-1,1,1 was recently synthesized [25#] and
exhibits the highest Xe association constant measured
in organic solvent, KA = 10 000 M
!1 at 293 K. This host
has a calculated internal volume of 81 A˚3, making the
xenon volume (42 A˚3) to host ratio equal to 0.52, which is
very close to Mecozzi and Rebek’s prescribed 0.55 ratio
for non-polar host–guest complexes mediated purely by
London forces [26]. Cryptophane-1,1,1 shows very slow
decomplexation kinetics, which not only produces a
narrow 129Xe NMR resonance useful for direct detection,
but also hinders the Xe exchange needed for indirect
detection [27##]. As this example shows, both thermo-
dynamics and kinetics impact the design of host mol-
ecules for xenon-biosensing applications.
Several water-soluble cryptophanes have been synthes-
ized to date, many with exceptional xenon-binding
characteristics [28,29,30#]. Huber’s water-soluble crypto-
phanes [28] replaced all six methoxy groups with OCH2-
COOH. The Xe affinity of hexa-acid cryptophane-A was
measured to be 6800 M!1 at 293 K. Conformational
changes were observed in the hexa-acid cryptophanes,
including a non-xenon-binding crown-saddle isomer. Our
98 Molecular Imaging
Figure 1
(A) Process of optical pumping to produce hyperpolarized 129Xe. (B) Schematic representation of hp 129Xe NMR spectrum showing (from left)
resonances of free xenon gas in aqueous solution, Xe-encapsulated biosensor bound to corresponding bioreceptor, and Xe encapsulated in free
biosensor. Legend shows components of biosensor: molecular cage, linker, and recognition moiety.
Current Opinion in Chemical Biology 2010, 14:97–104 www.sciencedirect.com
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In order to perform biosensing applications with water-soluble cryptophane-based 
129Xe contrast agents, two major strategies have been pursued: 1) localization of 129Xe 
signals at the desired target to enhance signal-to-noise and, 2) multiplexing, which would 
allow for the simultaneous detection of various disease biomarkers.45,81 The first strategy 
requires the synthesis of water-soluble cryptophane-A derivatives that bind tightly to 
xenon. As mentioned earlier, our lab has worked extensively on developing high affinity 
water-soluble cryptophane-A derivatives for in vivo applications where it is crucial for Xe 
to bind preferentially to cryptophanes and outcompete other proteins and fatty tissues 
present in the body. The binding affinity of Xe for proteins tends to be low and ranges 
from 10 M-1 for hemoglobin to 200 M-1 for myoglobin82,83 whereas the affinity for water-
soluble, tri-substituted cryptophanes synthesized in our lab ranges from 17,000 to 33,000 
M-1 in buffer and 22,000 M-1 in blood plasma at 293 K.40,41   The second strategy of 
multiplexing has also been developed in recent years where targeted cryptophane 
biosensors have been synthesized by conjugating the host molecule with a ligand that 
targets a biologically relevant biomarker (Figure 1.4b). The unbound biosensor has a 
unique NMR resonance and upon binding to the biomarker, additional 129Xe NMR peaks 
are formed that can be easily differentiated from the initial NMR resonance of the 
unbound biosensor. If a large variety of such biosensors could be developed where each 
targets a specific biosensor and had a unique chemical shift upon binding, a large number 
of targets could be investigated simultaneously, thereby leading to a more sensitive and 
accurate diagnosis. 
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The first example of such a targeted 129Xe biosensor consisted of a biotin-
conjugated cryptophane which gave a unique resonance at 70 ppm in solution.81 Upon 
binding to streptavidin, a new peak was formed at ~72.5 ppm (Figure 1.5). Therefore, a 
~2.5 ppm shift illustrates that the polarizable xenon atom is able to detect a difference in 
the chemical environment upon binding.81 Since xenon has a large chemical shift 
window, this proof-of-concept experiment indicated the potential of 129Xe NMR 
biosensors for multiplexing, whereby multiple biomarkers that indicate cancer formation 
can be simultaneously detected using MRI. Following this example, our lab developed an 
enzyme-responsive 129Xe biosensor that targeted the enzyme matrix metalloproteinase-7 
(MMP-7).84 MMP-7 is an important target since it is responsible for degrading 
extracellular matrix and is highly upregulated near tumors of the colon and breast.85-87 
Upon proteolysis of the peptide (MMP-7 substrate), two new NMR peaks (the biosensor 
consisted of two diastereomers) were formed 0.3 and 0.5 ppm upfield from the uncleaved 
NMR peak.84 Although the change in chemical shift was not very significant for in vivo 
applications, this study illustrated that enzymatic activity can be detected by using 129Xe 
NMR biosensors. Larger chemical shifts differences (3.0 to 7.5 ppm) upon binding were 
observed with a p-benzenesulfonamide-conjugated 129Xe biosensor used to target 
carbonic anhydrase isozymes I and II (Figure 1.6a, b).88 X-ray crystallography studies by 
the Christianson lab confirmed the presence of one xenon atom in the cryptophane cage 
as well as the binding of the benzenesulfonamide moiety in the carbonic anhydrase II 
binding site (Figure 1.6c).89 It is also interesting to note that for the 6-bond linker moiety, 
xenon was able to differentiate CA I from CA II (which have slightly different chemical 
shifts) while for the 7-bond linker, xenon was not only able to distinguish between the 
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two isozymes, but was also able to differentiate between the two diastereomers of the 
biosensor when bound to CA II.88 Therefore, the sensitivity of these contrast agents 
coupled with the significant chemical shift changes upon binding to biomarkers makes 
them promising candidates for 129Xe NMR biosensing.  
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Figure 1.5. a) Biotin-conjugated 129Xe biosensor, b) Hp 129Xe NMR resonance for the 
biosensor shifts from 70.2 to 72.5 ppm when biotin binds to streptavidin. Figure adapted 
from Spence, et al.81 
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Figure 1.3. Design of a Streptavidin Biosensor. 
 A) Streptavidin biosensor. Cryptophane-A is conjugated to a biotin ligand 
through a PEG maleimide linker.  The cationic Arg-Lys-Arg tripeptide helped to 
solubilize the biosensor. B) Upon binding strep avidi , chemical shift changed 
from 70.2 ppm to 72.5 ppm. Figure adapted from Spence et al.49 
A 
B 
 
 
 11 
 
 
OMe
OOMeO
OMe
O
OMe
O MeO O
O
O S
O
N
O
O
H
N
O
O
N
H
O
O
S
NHHN
O
Cys
Arg
Lys
Arg  
 
Figure 1.3. Design of a Streptavidin Biosensor. 
 A) Streptavidin biosensor. Cryptophane-A is conjugated to a biotin ligand 
through a PEG maleimide linker.  The cationic Arg-Lys-Arg tripeptide helped to 
solubilize the biosensor. B) Upon binding streptavidin, chemical shift changed 
from 70.2 ppm to 72.5 ppm. Figure adapted from Spence et al.49 
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Figure 1.6. a) Chemical structure of a benzenesulfonamide-conjugated cryptophane with 
a variable length linker that targets CA, b) 129Xe NMR spectroscopy showing the 
biosensors binding to CA I and II, c) Crystal structure showing the binding of the C8B 
biosensor to CAII where the Xe atom (green) is bound to cryptophane and the targeting 
sulfonamidate anion is coordinated to Zn2+ (gray). Adapted from Aaron and Chambers, et 
al.88,89 
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Figure 1.4. Design of a Carbonic Anhydrase Biosensor. 
 A.) Cryptophane-A was functionalized with two propionic acid groups to confer 
solubility and a benzylsulfonamide moiety with varying linker lengths. B.) 
Binding of the compounds (top row) to carbonic anhydrase I (middle row) and II 
(bottom row) generated downfield shifts ranging from 2.5 to 7.5 ppm. 
 
 
 
 
A. 
B. 
  
    
      
  
  
  
  
!!
!!
a)!
b)!
c)!
 18 
In order to pursue biological applications with 129Xe NMR biosensors, our lab 
performed the first successful delivery of water-soluble cryptophanes to cancer and 
normal cells by conjugating cryptophanes with cationic cell penetrating peptides which 
are able to cross cell membranes.90-92 The cellular delivery of the cryptophanes was 
confirmed by using confocal laser scanning microscopy. In order to target specific cancer 
biomarkers, the next step involved conjugating cryptophanes with targeting moieties and 
performing biological studies to determine cytotoxicity as well as the selectivity of 
delivering these biosensors to cancer cells overexpressing the targeted biomarkers. 
  
This thesis outlines the work done towards the development of a 129Xe biosensor 
to target the cancer biomarker, folate binding protein (FBP). FBP is a membrane-bound 
glycosylphosphatidylinositol (GPI)-linked membrane glycoprotein, which is highly 
upregulated (3-5 million copies/cell) in colon, breast, ovarian and brain tumors whereas it 
is underexpressed in most normal tissues.93-96 It is upregulated in fast growing cancer 
cells as folic acid, an essential component for one-carbon transfer reactions, has a high 
affinity for FBP and is transported into cells via folate-receptor mediated endocytosis. 
Previous studies have shown that FBP can effectively deliver folic acid-conjugated 
nanoparticles and imaging agents into cells.94 In this thesis, a new water-soluble 
cryptophane-A derivative was conjugated to a selectively protected (γ-conjugate) folate 
moiety. Confocal laser scanning microscopy, flow cytometry, cytotoxicity assays and 
hyperpolarized 129Xe NMR spectroscopy were performed to determine cellular viability, 
cellular delivery and the selectivity in delivering the biosensor to cancer cells 
overexpressing FBP. These studies are crucial for the development of a library of targeted 
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cryptophane-based 129Xe biosensors, each of which can be selectively delivered to the 
desired biomarkers, thereby enabling in vivo multiplexing during MRI. 
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1.3.  Hemicryptophanes: a new application in the development of molecular devices 
 
Related molecules to cryptophanes are hemicryptophanes, where one of the two 
CTV units is replaced by a N, O, S, or P atom to add different functionalities into the 
cage. As a result, the internal cavity tends to be dissymmetric.97 Hemicryptophanes have 
found a wide range of applications as organic hosts, metalloreceptors and catalysts. 
Recent examples of hemicryptophanes include the synthesis of chiral trialkanolamine-
based hemicryptophanes, which can act as metalloreceptors by forming an oxovanadium 
complex.98 Another type of hemicryptophane modified with a thiophosphorylated group 
has been confirmed by crystallographic analysis to encapsulate toluene.97 Additionally, 
the Ugi-type multi-component macrocyclization reaction was employed to synthesize 
diverse hemicryptophanes by using polyfunctional building blocks.99 Zn(II)–included 
hemicryptophane has also been shown to have significant catalytic activity in the 
hydrolysis of methyl para-nitrocarbonate.100 Triamide hemicryptophanes have also 
shown strong affinity for ion-pairs due to their heteroditopic character.101 
 
This thesis outlines a potentially new application for hemicryptophanes in the 
field of molecular devices and components. In recent years, there has been an explosive 
growth in the development of chemical systems that rely on electronic, chemical or 
mechanical effects to mimic the functions of macroscopic devices.102 These systems have 
not only allowed for the development of molecular-level machines,102 but also have 
provided a platform for understanding complex biological machines, e.g. bacterial 
 21 
flagella, ATPase pumps, etc. 103-110 Examples of such molecular mechanical systems 
include brakes, gears, propellers, turnstiles, and gyroscopes (Figure 1.7).105,111-114 
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Figure 1.7. Examples of molecular devices and components that rely on chemical, 
electronic and structural changes to mimic macroscopic devices. a) Mislow and 
Iwamura’s “molecular bevel gears”,113 b) Stoddart’s “shuttles”,115 c) Moore’s “molecular 
turnstiles”,116 d) Kelly’s “brakes”,117 and e) Feringa’s photochemically driven 
“motors”.118 Figure adapted from Khuong et al.119  
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In this thesis, a novel hemicryptophane was designed where one of the two CTV 
units was replaced by a tribenzylamine moiety. Although the new hemicrptophane was 
originally developed for host-guest applications, binding experiments revealed that the 
three rotating phenylene groups in the cage prevented the binding of small gaseous guests 
and solvent molecules at standard conditions. Upon further investigation, it was 
determined that the molecular structure and motions of this hemicryptophane closely 
resembled that of molecular gyroscopes. The criteria of designing molecular gyroscopes 
include rotary elements (rotators) that are connected to a static framework (stator). 
Among the several molecular gyroscopes that have been previously synthesized, one 
example consists of using metal-centered motifs to create gyroscopes where the central 
rotator is protected by a three-spoke stator.102,120-124 Another example includes the 
synthesis of amphidynamic crystals by Garcia-Garibay and coworkers where the central 
rotator of a solid-state gyroscope is protected by bulky substituents that form the 
stator.125-134 In both cases the rotator is protected by the stator to allow for low-barrier 
rotation. Yet due to the intercalation of solvent molecules or steric effects in solid-state 
studies, these gyroscopes have encountered undesirable barriers to rotation. Therefore, in 
this thesis we outline the design of a novel hemicryptophane, which unlike previous 
examples, has multiple, proximate rotators within one molecular system with an internal 
cavity small enough to deter the inclusion of solvent and gaseous molecules that could 
hamper rotation of the rotators. Also, we investigated the rate of rotation by 1H variable 
temperature (VT) NMR spectroscopy and molecular dynamics (MD) simulations.  The 
results outlined in this thesis indicate that hemicryptophanes make for compelling initial 
motifs for the synthesis of future molecular gyroscopes where the rotation could be 
 24 
controlled in a unidirectional fashion by incorporating either bulky substituents or dipole 
moments in the rotators.  
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ABSTRACT 
Xenon and radon have many similar properties, a difference being that all 35 
isotopes of radon (195Rn through 229Rn) are radioactive. Radon is a pervasive indoor air 
pollutant believed to cause significant incidence of lung cancer in many geographic 
regions, yet radon affinity for a discrete molecular species has never been determined.  
By comparison, the chemistry of xenon has been widely studied and applied in science 
and technology. Here, both noble gases were found to bind with exceptional affinity to 
tris-(triazole ethylamine) cryptophane, a new water-soluble organic host molecule. The 
cryptophane-xenon association constant, KA = 42,000 ± 2,000 M-1 at 293 K, was 
determined by isothermal titration calorimetry. This represents the highest measured 
xenon affinity for a host molecule.  The partitioning of radon between air and aqueous 
cryptophane solutions of varying concentration was determined radiometrically to give 
the cryptophane-radon association constant: KA = 49,000 ± 12,000 M-1 at 293 K.   
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INTRODUCTION 
Radon and xenon were isolated by Ramsay and co-workers more than one century 
ago, but since that time only the chemistry of xenon has received much attention. Xenon 
can be harvested from the atmosphere and has wide-ranging applications, from plasma 
televisions to ion propulsion systems for spacecraft. Radioactive 133Xe is used as a tracer 
for measuring physiological blood flow1 and also in detecting long-range fallout from 
nuclear weapons testing.2 Stable isotope 129Xe has a spin-½ nucleus that can be 
hyperpolarized to generate very large signals for magnetic resonance imaging (MRI).3 
Host molecules have been identified that bind xenon with high affinity,4 motivating 
further technological applications. Much less studied is radon, a radioactive noble gas 
that occurs as an intermediate species in the decay chain of uranium-238, an element 
ubiquitous in Earth’s crust. Epidemiological studies indicate that indoor accumulation of 
radon may cause a 5-31% increase in lung cancer risk per 100 Bq m-3 exposure.5 In 
Europe, such a level corresponds to 2% of all cancer deaths.5 The imperative to detect 
and remediate indoor radon motivates the study of radon chemistry, as do other scientific 
applications such as radon emission related to seismic activity.6 Prior radon-chemical 
studies have focused on adsorption of the gas to bulk substrates7 such as charcoal, silica 
gel and ice, and on the formation of radon halides.8 Radon hydrates have also been found 
to incorporate into the crystal lattices of SO2 and H2S hydrates.8 Until now, no discrete 
molecular species has been shown to bind radon, presenting an exciting frontier in noble 
gas research and host-guest chemistry. 
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 Radon is 10-15% larger by van der Waals volume than xenon (VXe ≈ 42 Å3, VRn ≈ 
47 Å3)9 and exhibits higher polarizability (αXe = 4.044 Å3,  αRn = 5.3 Å3),10 which should 
promote binding to void spaces. These observations led us to examine binding of radon to 
a cryptophane organic host molecule that has well established xenon affinity.4 
Cryptophane-A, consisting of two cyclotriguaiacylene caps joined by three ethylene 
linkers, has been shown to encapsulate xenon reversibly as a host-guest complex.11 
Recent X-ray crystallographic studies have shown that the internal volume of 
trisubstituted cryptophane-A derivatives can vary by more than 20%, depending on the 
size of the encapsulated guest.12 
 
Several cryptophane-A derivatives have been synthesized and shown by 
isothermal titration calorimetry (ITC), fluorescence quenching and NMR studies to 
exhibit xenon association constants as high as 33,000 ± 3,000 M-1 at 293 K in phosphate-
buffered water (Figure 2.1).13-16 Herein, we report a new cryptophane-A derivative, tris-
(triazole ethylamine) cryptophane (TTEC), with superior xenon-binding characteristics. 
A sensitive radiometric assay was developed for measuring radon binding to the same 
cryptophane. 
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 Figure 2.1. Water-soluble cryptophanes tris-(triazole propionic acid) (TTPC) and 
triacetic acid cryptophane-A (TAAC). Figure adapted from Hill, et al.15 
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RESULTS AND DISCUSSION 
 
Figure 2.2. Synthesis of tris-(triazole ethylamine) cryptophane-A (TTEC), top view 
shown. 
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Synthesis. The synthetic route leading to TTEC (compound 6) is outlined in Figure 2.2 
and briefly described here. A list of reagents, general methods, and synthetic procedures 
are provided in the Experimental procedures section. Tripropargyl cryptophane 4 was 
synthesized in 10 steps in 4% overall yield according to literature procedure and matched 
the reported physical constants and NMR spectrum.14 2-Azidoethylamine was 
synthesized in 93% yield, also following literature precedent.17 Reaction of 4 with three 
equivalents of 2-azidoethylamine was achieved via copper(I)-mediated [3 + 2] Huisgen 
cycloaddition18-21 to give the water-soluble TTEC (6). TTEC was purified by HPLC 
(Experimental procedures section provides representative trace) and isolated in 75% 
yield. TTEC identity was confirmed by 1H, 13C, and hyperpolarized 129Xe NMR 
spectroscopy (see Experimental procedures), in addition to matrix-assisted laser 
desorption/ionization mass spectrometry. 
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Figure 2.3. Enthalpogram of xenon binding to TTEC. Saturated aqueous xenon solution 
(5.05 mM) was titrated into 140 µM TTEC in phosphate buffer (20 mM, pH 7.5) at 293 
K.  
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Xenon Binding. To study the binding of xenon to TTEC, we utilized an ITC protocol 
previously developed in our laboratory.14 The experiments were performed by titrating 
TTEC in phosphate buffer (20 mM, pH 7.5) at 293 K with saturated xenon-in-water 
solution (5.05 mM at 1 atm, determined from the literature).22 The association constant 
was measured to be KA = 42,000 ± 2,000 M-1 at 293 K, which is the highest xenon 
affinity measured for any synthetic or naturally occurring host molecule. The cited 
uncertainty interval for KA is a standard uncertainty, assumed to correspond to a standard 
deviation, whose principal component was the uncertainty of the enthalpogram fit. 
Specifically, fitting of the enthalpogram (molar heat evolved vs. molar ratio, Figure 2.3) 
yielded thermodynamic parameters for the encapsulation: ∆H = -14.96 ± 0.30 kJ mol-1; -
T∆S = -10.97 kJ mol-1 at 293 K. Note that enthalpic and entropic components contributed 
similarly to the Gibbs free energy of xenon binding at 293 K (∆G = -25.93 kJ mol-1), 
which is believed to incorporate contributions from the dissolution of the clathrate water 
structure that surrounds xenon in solution, the release of one or more water molecules 
from the cryptophane cavity, and the non-covalent dispersion interactions between bound 
xenon and TTEC. 
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Figure 2.4. Diagrammatic representation of the radon binding affinity measurement, 
which exploits the partition of radon between aqueous and gaseous phases.  ‘LS’ refers to 
liquid scintillation counting.  L is the Ostwald coefficient of gas partition and KA is the 
radon association constant to be determined.  
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Radon Binding. Studies of radon binding used 222Rn evolved from the decay of 226Ra in 
four capsules, akin to NIST standards disseminated as SRM 4973 23 and consisting of 
polyethylene-encapsulated 226Ra solution.  These capsules generate a radium-free radon 
solution from decay of the radium and diffusion of the gaseous radon out of the 
capsules,24 and have been used to produce very small quantities of radon for use in 
calibrating environmental standards, e.g. those of drinking water.  In particular, only 
about two femtomoles of radon were available for use in our studies, rendering 
impractical the fluorescence quenching and ITC methods we previously used to measure 
xenon binding to cryptophane in water.14 Instead, we devised a method (Figure 2.4) 
wherein the binding of radon to TTEC could be measured radiometrically by liquid 
scintillation, a technique with detection efficiency approaching five due to equilibrated 
radon progeny.25 A related technique, involving gas-phase activity measurement, has 
been used to determine the partition of radon between water and various organic 
liquids.26 Radon partitions between gas and liquid phases according to a known ratio: the 
Ostwald solubility coefficient27 (L) for that liquid and temperature.  Cryptophane 
dissolved into the liquid phase of such a system acts as a radon sink and perturbs the 
system away from the Ostwald value in proportion to the binding affinity.  Thirty to forty 
minutes were allowed for radon to partition between the gas and liquid phases, with 
intermittent mixing. Subsequent sampling of the liquid phase allowed determination of 
the “apparent partition coefficient”, and from that KA.  We begin with the standard 
expression of KA: 
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Because [Rn] << [TTEC] (femtomole vs. micromole quantities), the simplification was 
made that [TTEC]free ≈ [TTEC].  Therefore,  
! 
KA =
AB
Afree
1
[TTEC]  
where AB and Afree are the bound and free radon activities in solution, which were not 
independently measured.  We have the definition of the Ostwald partition coefficient, 
 
where Vg and Vl are the gas and liquid phase volumes and Ag the gas-phase radon activity. 
Defining the apparent partition coefficient, Lʹ′ 
!L = (Afree + AB )VgAgVl
,  
we arrive at the relationship, 
         .][ LTTECLKL A +=ʹ′
   (1)
 
From LS counting before and after exposure to cryptophane, we determined Ag and (Afree 
+ AB), which in turn yielded Lʹ′.  Our Lʹ′ vs. [TTEC] data were fit by linear regression to 
equation (1) (Figure 2.5).  By this method, the affinity of TTEC for radon was found to 
be KA = 49,000 ± 12,000 M-1 at 293 K.  The standard uncertainty given here for KA 
derived from the 95% confidence intervals on the parameters of fit to the apparent 
partition coefficients vs. TTEC concentration series (Equation 1 and Figure 2.5). The 
€ 
L = [Rn] free[Rn]g
=
AfreeVg
AgVl
,
  
K A = 
[ Bound ] 
[ TTEC ] free [ Rn ] free 
. 
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uncertainty in the radon assays used to derive the partition coefficients was negligible.  
These data were well fit by a linear model, with R2 = 0.87.  Radon activity measured for 
reaction vessels containing no cryptophane deviated from this line, as expected when the 
[Rn] << [TTEC] condition no longer holds.    
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Figure 2.5. Apparent partition coefficient, Lʹ′, as a function of cryptophane concentration.  
The circles represent reaction vessels that contained no cryptophane; the squares 
represent a series of increasing cryptophane concentrations in the non-saturated regime, 
fitted to equation (1).   
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From these experiments, radon was found to bind TTEC with a free energy of 
binding 0.4 kJ/mol more negative than in the case of xenon (-26.3 vs. -25.9 kJ/mol).  
However, radon is also more soluble in water solution than xenon and therefore liberates 
less free energy upon desolvation (-20.71 kJ/mol, Rn vs. -23.18 kJ/mol, Xe; est.).28 
Accounting for this, we estimate that supramolecular interactions of the TTEC-Rn 
complex, e.g. balance of improved dispersion interactions and entropic cost of 
confinement, produce a free energy of binding 2.9 kJ/mol stronger than in the TTEC-Xe 
complex.  Our previous crystallographic study showed that the internal volume of 
trisubstituted cryptophane-A derivatives bound to Xe is roughly 87 Å3 and can expand to 
~100 Å3 to accommodate a much larger (71 Å3) CDCl3 guest.12 We can assume that 
TTEC bound to either Xe or Rn adopts a very similar geometry to the previous 4-Xe 
crystal structure (Figure 2.6).12 As evidenced by this structure, Xe underfills the 
cryptophane cavity, interacting over tenths of angstroms with the phenyl carbon atoms in 
both cyclotriguaiacylene caps. The somewhat larger, more polarizable Rn atom is 
expected to exhibit stronger van der Waals interactions with TTEC than Xe, as supported 
by the measured enhancement in free energy of binding. 
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Figure 2.6. Structure of 4-Xe complex determined from X-ray crystallography.12 van der 
Waals radii are shown for Xe (blue sphere) and carbon atoms of one pair of opposing 
phenyl groups.  Hydrogen atoms have been removed for clarity. Rn is expected to bind to 
the same site in TTEC, while occupying 10-15% more of the interior cavity volume. 
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Despite the institution of government-sponsored detection and remediation 
programs in many countries,29 contemporary assessments show that radon exposure 
remains the second leading cause of lung cancer, after smoking, in the United States.30,31 
While the environmental health risks posed by radon are well recognized, studies of 
radon binding to well-defined synthetic or biological targets have not been performed; 
studies have tended to focus on the association of radon progeny, not radon itself.32 
Challenges in this work have been to obtain pure 222Rn and make binding measurements 
on very small quantities of material. In the current study, pure radon was obtained by 
sealing 226RaCl2 solution inside of polyethylene capsules permeable only to the gaseous 
emanation.  These capsules, placed in a sealed 10.6-mL water-filled vessel, generated a 
useful concentration of 222Rn within roughly one week as a steady state was approached.  
This solution provided sufficient 222Rn for tens of binding measurements. This method 
requires the radium-filled capsules to be properly sealed, and all 222Rn manipulations 
must be performed using gas-tight syringes inside of a laboratory fume hood. With these 
precautions, this method has broad utility for the study of radon binding to many different 
biological samples, biomolecules, or other small-molecule hosts.  
 
The concepts of supramolecular chemistry33,34 can be usefully applied to the study 
of radon binding. For example, many organic cavitands should bind radon with 
appreciable affinity, based on radon’s considerable polarizability and molecular volume, 
which is similar to that of dichloromethane. This study showed that a water-soluble 
cryptophane-A derivative binds radon with considerable affinity. Indeed, TTEC may 
provide a nearly optimal cavity for radon as its internal volume (~90 Å3, assuming 
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modest expansion from the average 4-Xe structure)12 is approximately twice the radon 
atomic volume.35 Furthermore, in lieu of three ethylamine groups, tripropargylated 4 can 
be reacted with a wide variety of water-solubilizing azido-linkers that may fine-tune the 
host-noble gas interaction.12-14  
 
Considering our previous study of the analogous tris(triazole propionic acid) 
cryptophane,14 it is striking that a tris-carboxylate to tris-amine substitution at the 
cryptophane periphery increased the Xe association constant from 17,000 M-1 to 42,000 
M-1 at 293 K. In order to explore the role of electrostatic interactions, we investigated 
xenon binding to TTEC at pH 2.5 (Figure 2.7) and 7.5 (Figure 2.3). As shown in Figures 
2.8 and 2.9, hyperpolarized 129Xe NMR spectroscopy gave comparable chemical shifts at 
298 K for TTEC-129Xe at pH 2.5 (63.8 ppm) and pH 7.5 (64.3 ppm), which is indicative 
of very similar Xe binding environments within the cryptophane. Over this pH range the 
compound went from a state of predominantly triple protonation at pH 2.5 to mostly 
single protonation at pH 7.5 while remaining in solution (Figure 2.10). Slightly higher Xe 
binding affinity was observed by ITC at pH 7.5 than pH 2.5 (KA = 42,000 ± 2,000 M-1 vs. 
KA = 34,000 ± 1,000 M-1 at 293 K, Figure 2.7). Thus, it appears that electrostatic 
interactions, as well as other effects such as cryptophane solvation, are responsible for the 
enhanced Xe binding observed in TTEC.    
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Figure 2.7. Enthalpogram of 83 µM TTEC (6) in phosphate buffer (20 mM, pH 2.5) at 
293 K titrated with saturated aqueous xenon solution (5.05 mM).  
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Figure 2.8. Hyperpolarized 129Xe NMR spectrum showing xenon bound to TTEC (6) in 
20 mM phosphate buffer, pH 7.5.  
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Figure 2.9. Hyperpolarized 129Xe NMR spectrum showing xenon bound to TTEC (6) in 
20 mM phosphate buffer, pH 2.5.  
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Figure 2.10. Titration curve showing the titration of 0.279 micromoles TTEC (6) in 1 mL 
of 100 mM NaCl with small aliquots of 50 mM HCl. The acid-base titrations were 
performed following the same methodology reported previously.15 
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CONCLUSION 
The development of high-affinity Xe-binding cages is an area of active 
investigation and is critical to the burgeoning field of xenon biosensing.16,36,37 Synthetic 
host molecules designed to bind xenon in cells or in vivo must compete against a wide 
variety of biological substrates.  Xenon is lipophilic and exhibits affinity for cavities in 
macromolecular interiors. Xenon's lipophilic behavior has been shown from its partition 
with long-chain hydrocarbons38,39 and from its in vitro40 and in vivo41 partition with fatty 
tissue. Xenon binding to myoglobin has been well characterized by NMR 
spectroscopy42,43 and X-ray crystallography,44 and metmyoglobin-Xe association 
constants have been measured to be ~200 M-1 and 10 M-1.44,45 Comparable affinities have 
been determined for other naturally occurring sites in hemoglobin,43 lipoxygenase,46 and 
lipid transfer protein,47 as well as specially designed hydrophobic cavities in T4 
lysozyme,48 ribose-binding protein,49 and other examples.50,51 We showed previously that 
xenon binds water-soluble cryptophanes ~1.5-fold less avidly in human plasma than in 
aqueous buffer solution.14 Thus, the design of higher affinity xenon-binding molecules 
such as TTEC extends the range of possible biological applications. Biologically targeted 
cryptophanes are under development as potential 129Xe MRI contrast agents, as 
demonstrated by xenon biosensors for the prototypical biotin-avidin interaction52,53 and 
other proteins,54-56 as well as cell studies.57-59 This demonstration of radon binding to 
cryptophane raises similar possibilities of molecularly functionalized radon binders for 
biological, environmental, and materials applications involving radon delivery, 
sequestration, or detection.  
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Finally, it is significant that xenon and radon showed similarly tight binding for a 
well-defined molecular cavity (TTEC). This suggests that radon, which like xenon is 
known to be lipophilic,26,60 also binds with appreciable affinity to many proteins, 
surfactants, and small air spaces in the lung and other regions of the body. Radiometric 
binding methods developed in the course of this work will enable quantitative 
comparisons of radon binding to various biomolecular targets, as a means of assessing 
environmental health risk. Such information may ultimately be useful in developing more 
effective mitigation strategies for this indoor pollutant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 60 
EXPERIMENTAL PROCEDURES 
Reagents.  Organic reagents and solvents were used as purchased from the following 
commercial sources:    
 Sigma-Aldrich: methanol, 2,6-lutidine; Acros: cesium carbonate, anhydrous 
dimethylsulfoxide (DMSO), anhydrous dimethylformamide (DMF), 70% perchloric acid, 
d6-DMSO, CDCl3; Fisher: sodium chloride, potassium phosphate, ethyl acetate, 
dichloromethane, hydrochloric acid, sodium hydroxide, sodium sulfate, acetone, hexanes; 
Cambridge Isotope Laboratories:  deuterium oxide; Airco Industrial Gases: research-
grade xenon gas.    
 
General Methods.  All organic reactions were carried out under nitrogen atmosphere.  
1H NMR (500.14 MHz) and 13C NMR (125.77 MHz) spectra were obtained on a Bruker 
AMX 500 spectrometer at the University of Pennsylvania NMR facility. Electrospray 
ionization mass spectrometry was performed in low-resolution mode on a Micromass LC 
Platform and in high-resolution mode on a Micromass Autospec while matrix-assisted 
laser desorption/ionization spectrometry (MALDI) was performed on a Bruker Daltonic 
Ultraflex III MALDI-TOF-TOF at the Mass Spectrometry Center in the Chemistry 
Department at the University of Pennsylvania.  Isothermal titration calorimetry (ITC) was 
performed using a MicroCal VP-ITC titration microcalorimeter (Northampton, MA). For 
ITC measurements in buffer, solutions were prepared with deionized (DI) water obtained 
from Mar Cor Premium Grade Mixed Bed Service Deionization (18.2 megohm-cm 
resistivity at 25 °C).  Column chromatography was performed using 60 Å porosity, 40-75 
µm particle size silica gel from Sorbent Technologies. Thin layer chromatography (TLC) 
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was performed using silica gel plates with UV light at 254 nm for detection. HPLC 
analysis was performed on an Agilent 1100 system equipped with a quaternary pump and 
diode array detector using a Varian Microsorb-MV 300-5 C8 column (4.6 × 250 mm, 5 
µm). The gradient eluent was composed of two solvents: 0.1% aqueous TFA (solvent A) 
and a 0.1% solution of TFA in CH3CN (solvent B). UV-visible spectra were measured 
using a diode-array Agilent 89090A spectrophotometer.  
 
Synthesis. Cyclotriguaiacylene (1), and [3-propargyloxy-4-(2-
iodoethoxy)phenyl]methanol (2) were synthesized using previously published 
protocols.56 The NMR spectra and physical constants also matched the reported literature 
data.56    
2,7,12-Tris[2-[4-(hydroxymethyl)-2-propargyloxyphenoxy]ethoxy]-3,8,13-trimethoxy-
10,15-dihydro-2H-tribenzo[a,d,g]cyclononene (3), and tripropargyl cryptophane (4) were 
also synthesized using previous protocols.14 The identity and purity of the compounds 
were confirmed by matching the NMR spectra and physical constants to reported 
literature data.14 2-Azidoethylamine (5) was synthesized in 93% yield, also following 
literature precedent.17 
Tris(triazole ethylamine) cryptophane (6, TTEC). Tripropargyl cryptophane (4) (10.13 
mg, 0.01049 mmol, 1.0 equiv.), 2-azidoethylamine (5) (4.47 mg, 0.0520 mmol, 5.0 
equiv.), copper (II) sulfate (0.83 mg, 0.0052 mmol, 0.5 equiv.), 2,6 lutidine (0.11 mg, 
0.0010 mmol, 0.1 equiv.), and sodium ascorbate (82.14 mg, 0.4146 mmol, 40 equiv.) 
were added to a glass vial with septum cap. Dry DMSO (0.5 mL) was added and the 
reaction was magnetically stirred under nitrogen overnight.  The product was purified 
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using two methods: 1) 0.1 % TFA in DI water was added to the reaction mixture which 
led to the precipitation of the product TTEC (6) which was centrifuged and the 
supernatant discarded.  The white pellet was resuspended in DI water and precipitated by 
adding 0.1 % TFA and centrifuged again to separate the supernatant.  This was repeated 
twice after which the white precipitate was dried under vacuum; 2) The product was also 
purified using the HPLC gradient 0.1% TFA in 95% water: 5% acetonitrile to 0.1% TFA 
in 20% water: 80% acetonitrile over 75 min. This resulted in 9.73 mg (75% yield) of 
TTEC (6) as a white powder.  1H NMR (500 MHz, d6-DMSO): σ 8.20 (s, 3H), 7.09 (s, 
3H), 6.88 (s, 3H), 6.82 (s, 3H), 6.80 (s, 3H), 5.12-5.03 (m, 6H), 4.52-4.49 (m, 6H), 4.42 
(s, 6H), 4.21-4.09 (m, 18H), 3.51 (s, 9H), 3.38 (d, J = 13.8 Hz, 3H). Heq and α-amino 
protons with a total integration of 6H were hidden under residual water peak. 13C NMR 
(125 MHz, d6-DMSO) 148.8, 147.8, 146.0, 145.7, 143.3, 133.8, 133.5, 132.6, 131.7, 
124.5, 120.7, 119.0, 117.0, 115.0, 68.8, 68.3, 62.8, 56.0, 49.3, 35.0, 29.1; MALDI MS 
calcd. for C66H72N12O12 (M + Na+) 1247.539; found 1247.724. 
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Hyperpolarized 129Xe NMR Spectroscopy. A home-built version of the previously 
commercially available Nycomed-Amersham (now GE) IGI.Xe.2000 129Xe 
hyperpolarizer was used to generate the hyperpolarized 129Xe gas. A gas mixture of 89% 
N2, 10% He, and 1% natural abundance Xe (Spectra Gases) was flowed through the 
hyperpolarizer. 129Xe was hyperpolarized to 10-15% after being cryogenically separated, 
accumulated, thawed, and collected in CAV NMR tubes (New Era). After Xe collection, 
NMR tubes were shaken vigorously to mix cryptophane solutions with Xe. 
 
All 129Xe NMR measurements were carried out on a 500 MHz Bruker BioDRX 
NMR spectrometer at the University of Pennsylvania NMR Facility. RF pulse frequency 
for 129Xe was 138.12 MHz. Samples were observed using either a 5 mm PABBO NMR 
probe or a similar 10 mm probe. 
 
129Xe NMR spectra were acquired using the Exchange Signal Averaging (ESA) 
method.61 Selective pulses (90º flip angle, EBurp1 shaped) were generated at the 
Xe@cryptophane resonance frequencies. Each pulse lasted 5 ms, which gave a 
designated excitation region ~1 kHz. All spectra were signal averaged by 40 scans. A 
delay of 0.15 s was given between scans to allow polarized Xe to exchange in and 
depolarized Xe to exchange out of the cryptophane cavity. Sample temperature was 
controlled by VT unit on NMR spectrometer to 27 ± 1 ºC. 
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HPLC trace for TTEC (6). Column: Microsorb-MV 300-5 C8 250 x 4.6 mm (Varian); 
flow rate: 1 mL/min; injected volume: 500 µL; wavelength detection: 280 nm. HPLC 
gradient 0.1% TFA in 95% water: 5% acetonitrile to 0.1% TFA in 20% water: 80% 
acetonitrile over 75 min. Retention time of TTEC: 25.16 min. 
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1H NMR of TTEC (6) in d6-DMSO at 298K 
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13C NMR of TTEC (6) in d6-DMSO at 298K 
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Xenon Binding Study. Isothermal titration calorimetry (ITC) was performed using a 
MicroCal VP-ITC titration microcalorimeter (Northampton, MA).62 TTEC was dissolved 
in phosphate buffer (20 mM, pH 7.5) and the concentration (140 µM) was determined by 
UV-vis spectroscopy according to the extinction coefficient of TTEC at 280 nm (ε280 = 
12,400 M-1cm-1). The preparation of saturated aqueous xenon solution and the 
determination of xenon concentration at 293 K were performed following the same 
methodology reported previously.14,22 The titrations were carried out at 293 K; 1.8 mL of 
the TTEC in 20 mM phosphate buffer was placed in the calorimeter cell, and the 
saturated xenon-water solution was loaded into the microsyringe.  
 
The titration was performed by the sequential addition of 15 µL aliquots of xenon 
solution (for a total of 19 injections) at 5-min intervals. The heat of reaction per injection 
(micro-calories per second) was determined by integration of the peak areas (ORIGIN 
7.0, MicroCal software). The values of the binding enthalpy (∆Ho), the stoichiometry of 
binding (n), and the association constant (KA) were obtained from fitting the heat evolved 
per mole of xenon injected versus the xenon/TTEC molar ratio using the same software. 
Three control experiments (see Experimental procedures) were performed with each 
phosphate buffer (20 mM) at pH 7.5 or pH 2.5: 1) saturated xenon solution titrated into 
buffer; 2) water titrated into TTEC-buffer solution; and 3) water titrated into buffer to 
determine the heats of dilution. Processes #1 and #2 were subtracted from, and #3 was 
added back to, the corresponding TTEC-xenon binding enthalpogram before curve 
fitting. 
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ITC buffer controls at 293 K. Buffer is 20 mM phosphate, pH 7.5. a) Water titrated into 
buffer. b) Water titrated into a solution of 140 µM TTEC (6) in buffer. c) Xenon-
saturated water ([Xe] = 5.05 mM) titrated into buffer. 
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ITC buffer controls at 293 K. Buffer is 20 mM phosphate buffer, pH 2.5. a) Buffer 
titrated into buffer. b) Buffer titrated into a solution of 83 µM TTEC (6) in buffer. c) 
Xenon-saturated buffer ([Xe] = 5.05 mM) titrated into buffer. 
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Radon Binding Study. Radon was generated from 63 kBq 226Ra in four polyethylene 
capsules submersed in a water-filled 10.6 mL vessel sealed with an aluminum-lined 
septum.  Radon was allowed to accumulate in the water for 8 days prior to the 
experiment. The emanation fraction (i.e., the ratio of accumulated 222Rn to the total 
generated from 226Ra decay) for the capsules was about 30%. Stock TTEC solution 
concentration (48.3 µM) was determined by UV-vis spectroscopy and radon-in-water 
solution concentration (1.002 pM) by LS counting. Glass vials (1.1-mL Chromacol screw 
top, Supelco, Bellefonte, PA, USA) sealed with PTFE septa were filled by micropipette 
with varying concentrations of cryptophane solution (0.49-5.29 nmol in 120 µL; six 
concentrations, each in duplicate, and three null trials), and with radon-in-water solution 
(400 µL) from the generator, by 10-mL glass, gas-tight Hamilton syringe.  The rest of the 
vial was left as airspace.  The samples were incubated for 30-40 min at 293 K; each vial 
was subjected to two 5-sec vortex mixings, one each at the beginning and end of the 
incubation.  A 400 µL sample was withdrawn from each vial and injected beneath the 
surface of approximately 19 mL LS cocktail that consisted of a commercial scintillation 
fluid (Ultima GAB, PerkinElmer, Waltham MA, USA) having a 5% water fraction in a 
22-mL Al-foil lined, glass LS vial.  LS counting was done using automated equipment 
after allowing time for radon to equilibrate with its daughter nuclides.  Each sample was 
counted for 1 h in two apparatuses with different operational parameters (Beckman 
Coulter, Brea, CA, USA; Wallac, PerkinElmer, Waltham, MA, USA).  All liquid 
transfers by micropipette and syringe, as well as the precise volumes of the vials, were 
quantified gravimetrically.   
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 The radon determinations were based on well-established LS procedures for the 
assay of gravimetrically-determined aliquots of aqueous solutions containing radon in 
radioactive equilibrium with its short-lived daughter products.23 Raw LS data were 
corrected for background (< 0.3% correction), for the radon content in the airspace above 
the cocktail in the LS vials (approx. 0.7 % correction), and for radioactive decay to a 
common reference time. Counting was initiated after a minimum of 4 h to ensure that the 
radon daughters were in radioactive equilibrium. Each source was measured for 20 min 
over a period of 0.2 to 4.9 days on 6 to 10 occasions. The corrected net counting rates 
were observed to decay with the radon half-life, indicating that there was no radium 
leakage from the capsules.  Corrected data were fitted to equation (1) by least-squares 
linear regression using MATLAB (Mathworks, Natick, MA, USA) to obtain KA and L.   
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CHAPTER 3: TARGETING THE FOLATE RECEPTOR 
WITH A FOLATE-CONJUGATED CRYPTOPHANE FOR 
CANCER DETECTION  
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ABSTRACT 
 
Folate-conjugated cryptophane enables the targeting and delivery of cryptophane 
to cells overexpressing folate receptors, which are overexpressed in many human cancers. 
The cryptophane biosensor was synthesized in 19 nonlinear steps, which included 
functionalization with a folate recognition moiety, solubilizing peptide group and Cy3 
dye. Cellular internalization was monitored by confocal laser scanning microscopy 
(CLSM). A competitive blocking study confirmed cryptophane endocytosis through a 
folate receptor-mediated pathway. Flow cytometry revealed 10-fold higher cellular 
internalization in cancer cells overexpressing folate receptors (KB cells) compared to 
cells underexpressing folate receptors (HT-1080 cells). The biosensor was determined to 
be relatively non-toxic in low folate receptor expressing HT-1080 cells by MTT assay at 
the micromolar cryptophane concentrations typically used for hyperpolarized 129Xe NMR 
biosensing experiments. In folate overexpressing KB cells, the viability ranged from 
100% to 80% from 0 µM to 10 µM and dropped to 50% at 38 µM. 129Xe NMR studies 
were performed and the resulting peak at 65 ppm confirmed xenon binding to the folate-
conjugated cryptophane. Studies are currently underway to detect the binding of the 
folate-conjugated biosensor to monomeric folate binding protein at nanomolar or 
picomolar concentrations using Hyper-CEST NMR techniques. 
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INTRODUCTION 
 
As mentioned in Chapter 1, magnetic resonance imaging (MRI) is a noninvasive 
medical imaging technique used to scan deep tissues with high spatial resolution. 
Although it can provide high contrast images of different tissues such as organs and 
bones, it is limited by low sensitivity due to the high background-to-signal ratio. In order 
to increase signal, especially when imaging vascular tissues or analyzing brain perfusion, 
gadolinium- or iron-oxide-based contrast agents are commonly used. However, there are 
limitations to these imaging agents. Early and accurate diagnoses of disease states 
increasingly rely upon information gleaned from molecular imaging of protein 
biomarkers or metabolic processes. There are now many examples using PET and 
SPECT imaging agents with readily detected radioactive nuclei.1 By comparison, current 
MRI contrast agents have limited ability to detect proteins of low abundance in cells.2,3,4 
The goal of making “smart” MRI contrast agents that produce readily measured signal in 
response to environmental cues has led to investigation of alternate nuclei, including 
hyperpolarized 129Xe, 13C, 38Kr and 3He.5-8 
 
  129Xe is an attractive option for imaging because of its nontoxicity, chemical-shift 
sensitivity to its molecular environment and hyperpolarizability. Additionally, water-
soluble tris-(triazole ethylamine) and tris-carboxylate derivatives of cryptophane-A have 
been developed that bind xenon with large association constants, KA = 17,000-42,000 M-1 
in buffer at 293 K. Additionally, one cryptophane was shown to bind Xe in human 
plasma with appreciable affinity, KA = 22,000 M-1 at 310K.9 This has led to the synthesis 
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of cryptophane-based biosensors that are conjugated to various ligands via a hydroxyl or 
propargyl group. As mentioned in Chapter 1, these include a biotin-modified cryptophane 
biosensor that can detect streptavidin in vitro,10-13 an enzyme-responsive 129Xe NMR 
biosensor for the detection of matrix metalloproteinase-7 (MMP-7),14 and a series of 
benzenesulfonamide-functionalized cryptophane-A derivatives that exhibited the largest 
isozyme-specific chemical shift changes (3.0-7.5 ppm), upon binding carbonic 
anhydrases I and II.15 Another recent example included the synthesis of a peptide-labeled 
129Xe biosensor by Schlundt et al. that produced a 1 ppm downfield shift upon binding to 
a major histocompatibility complex (MHC) class II protein.16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
The delivery of cryptophanes using cell penetrating peptides or by targeting αvβ3 integrin 
receptors into cancer and normal cells has also been demonstrated.17,18 The cryptophanes 
were minimally cytotoxic and intracellular concentrations of approximately 100 µM were 
achieved, which should be sufficient for in vivo hyperpolarized 129Xe MRI studies.17,18 
 
In cells, there are three types of transporters that are responsible for the uptake of 
folate. These include RFC (reduced folate carrier),19 proton-coupled high affinity folate 
transporter,20 and folate receptor (FR, also known as high affinity folate binding 
protein).21 Folate receptors are cell surface glycosylphosphatidylinositol (GPI)-linked 
membrane glycoproteins with molecular weights ranging from 38,000 to 45,000 Da.22 It 
has a high binding affinity (KD ≈ 0.1-1 nM with a 1:1 stoichiometry) for folic acid and 5-
methyltetrahydrofolate.22 FR is mainly located on the luminal surface of polarized 
epithelial cells. In humans, FR has 4 different types of isoforms: α, β, γ, and δ, where 
isoforms α and β are membrane bound.21 Among them, FRα is overexpressed in non-
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mucinous adenocarcinomas of the ovary, cervix, uterus, ependymal brain tumors,whereas 
normal cell lines have very low FR expression.23-26 FR expression in normal tissues 
mostly is found in polarized epithelial cells in the proximal kidney tubules, choroid 
plexus, etc.25,27-31 FRα is overexpressed in 90% of ovarian carcinomas and higher levels 
of expression are generally associated with poorly differentiated and aggressive 
tumors.31,32 It is believed that FRα is overexpressed because the fast growth rate of cancer 
cells requires more folic acid.21 Folic acid is an essential component of the one-carbon 
transfer reactions which are crucial for one-carbon, nucleic acid, and amino acid 
metabolism, as well as the synthesis and proliferation of cells.33 For instance, in ovarian 
cancer cells it was possible to limit cancer cell growth by using a FA-antibody to 
decrease FRα expression.34 
 
Although FRα is expressed in normal tissues, their distribution on the luminal 
surface of epithelial cells ensures that they are not directly accessible through the blood 
stream.21 Therefore, it is expected that for in vivo studies, folate-conjugated agents will be 
selectively targeted to tumors overexpressing FRα. Previous studies have shown that FRα 
can transport folic acid as well as folic acid conjugates (e.g., imaging agents, proteins, 
nanoparticles) via receptor-mediated endocytosis (Figure 3.1).23 Therefore, FRα is a 
potential cancer biomarker that would indicate the presence of cancerous abnormalities if 
detected by the folate-conjugated 129Xe biosensor. Additionally, folate remains 
essentially unaltered after endocytosis and is stable for several hours after the uptake by 
cancer cells.35 All of these characteristics make FRα an attractive marker for the 129Xe 
biosensor to detect. 
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Figure 3.1. Scheme of the FRα-mediated endocytosis of a folic acid drug conjugate. 
Folate conjugates bind FRα with high affinity and are internalized into endosomes. As 
proton pumps acidify the lumen of late-stage endosomes, the folate conjugates are 
released into the cell cytosol.36   
 
 
 
 
 
 
 
It has been known for nearly a decade that simple cova-
lent attachment of folic acid to virtually any macromole-
cule produces a conjugate that can be internalized into 
FR-bearing cells in an identical fashion to that of free folic
acid17. Numerous publications have emerged to elucidate
the mechanism and to further define the advantages as
well as the limitations of this technology. To date, folate
conjugates of radiopharmaceutical agents18–23, MRI con-
trast agents24, low molecular weight chemotherapeutic
agents25, antisense oligonucleotides and ribozymes26–30,
proteins and protein toxins17,31–35, immunotherapeutic
agents36–39, liposomes with entrapped drugs40–44 and plas-
mids45–51 have all been successfully delivered to FR-express-
ing cancer cells. The objective of this review will be to
focus on only a few of the aforementioned techniques with
regard to their currently known preclinical or clinical in-
vestigations, as well as to provide greater insight into the
use of folate-mediated macromolecule delivery.
Radiodiagnostic imaging
The field of nuclear medicine has been revitalized with the
advent of tissue-specific radiopharmaceutical-targeting
technologies. Ligands capable of concentrating at patho-
logical sites have been derivatised with chelator–radio-
nuclide complexes and used as non-invasive probes for 
diagnostic imaging purposes. For instance, monoclonal 
antibodies, somatostatin analogs, vasoactive intestinal
peptides and folic acid have all been used as ligands to lo-
calize radionuclides to tumors18–23,52–54. Applications with
monoclonal antibodies, and truncated derivatives thereof,
initially received the most attention because it was 
believed that precise, or perhaps superior, tumor-specific
targeting might be easily achieved. Unfortunately, this 
approach was subsequently found to be technically chal-
lenging and inferior to other methods, because:
(1) antibodies have prolonged circulation times owing 
to their large molecular size (an unfavorable trait for
imaging purposes);
(2) antibodies can be immunogenic, forcing their laborious
humanization whenever multiple doses were anticipated;
(3) antibodies are expensive to produce; and
(4) tumor to non-target tissue ratios (T:NT) of antibody-
linked radionuclides were suboptimal55–57.
Thus, more focus has recently been directed towards the
use of smaller tumor-specific ligands that do not suffer
from such limitations.
Chronologically, the first folic acid conjugate described
for in vivo tumor imaging was a histamine derivative con-
taining 125-Iodine (125I;Ref. 58). Although impressive tumor
images were obtained with this conjugate, it was not con-
sidered to be a relevant clinical candidate owing to the
long-lived 125I radionuclide component. Subsequent reports
described the synthesis and use of folate-deferoxamine for
tumor targeting18,19. Deferoxamine chelates 67-Gallium (67Ga),
a gamma-emitting radionuclide that has a half-life of 78 h.
Favorable pharmacokinetic biodistribution profiles and
high T:NT ratios were obtained with the folate–deferoxam-
ine conjugate in a tumor-bearing nude mouse model. Un-
fortunately, partial hepatobiliary clearance was observed,
and further preclinical development was stopped because of
anticipated problems in accurately imaging regio-abdominal
locations in humans. This obstacle was easily overcome,
however, by simply replacing the deferoxamine chelator
with diethylenetriamine penta-acetic acid (DTPA), an effi-
cient chelator of 111-Indium (111In; 68 h half-life). 111In-
DTPA–folate displayed very similar tumor-accumulating
45
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In this study, a folate-conjugated water-soluble cryptophane biosensor (Figure 
3.2) was synthesized, which was envisioned to target cancer cells that are known to 
overexpress FRα. The biosensor was composed of four functional components. The first 
was the monopropargylated cryptophane-A derivative, which is known to bind xenon in 
organic and aqueous solvents.14 The second part was the solubilizing moiety, which 
consists of a polycationic peptide (RKR) where the positive charges are deliberately 
broken up by a polyethyleneglycol unit (PEG). This is because polycation sequences of 
five or greater peptide units are known to induce non-specific uptake of peptide 
conjugates into cells.37 The third component consisted of the Cy3 fluorescent dye, which 
is conjugated through a maleimide linkage to the cysteine residue on the peptide 
sequence. The dye was included to assist in the visualization of the biosensor in both FR+ 
and FR- cells by confocal laser scanning microscopy and flow cytometry. Lastly, a folate 
recognition moiety that has a high affinity for FRα was conjugated via an orthogonally 
protected lysine on the peptide sequence. The last step in the synthesis involved the 
conjugation of the N-terminal azide of the peptide-folate conjugate to monopropargylated 
cryptophane by a Cu(I)-catalyzed [3+2] Huisgen cycloaddition.38-40 Selective cell uptake 
and cytotoxicity studies were performed using confocal laser scanning microscopy, flow 
cytometry and MTT assays for KB and HT-1080 cancer cells.  
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Figure 3.2. Structure of the FRα-targeting 129Xe NMR biosensor, with a xenon-binding 
cryptophane, solubilizing peptide, FRα targeting moiety (blue) and fluorescent Cy3 dye 
for in vitro studies (red).  
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RESULTS AND DISCUSSION 
Synthesis and characterization of folate-cryptophane conjugate 
 
Synthesis of α-[2-(Trimethylsilyl)ethoxy]-2-N-[2-(trimethylsilyl)- 
ethoxycarbonyl]folic acid (“folate recognition moiety”). The conjugation of folic acid 
to the peptide sequence with DCC would lead to the synthesis of a mixture of α-folate 
and γ-folate conjugates. Because only the γ-conjugate is recognized by the FRα receptor, 
a selectively protected folic acid derivative 7 was synthesized in 5 nonlinear steps in 13% 
overall yield (Scheme 3.1).41 The folate recognition moiety was prepared from two 
intermediates: the 2-N-teoc-pteroic acid derivative, where the teoc group is 2-
(trimethylsilyl)ethoxycarbonyl, and the α-carboxyl-protected glutamic acid.41 Folic acid 
(1) undergoes enzymatic hydrolysis with carboxypeptidase-G to give pteroic acid (2). 
Carbonyldiimidazole (CDI) and 2-trimethylsilylethanol in dry dimethyl sulfoxide 
(DMSO) were added to the crude pteroic acid to produce the protected pteroic acid, 1-(2-
N-teoc-pteroyl)imidazole (3) in 62% yield. In order to synthesize the second 
intermediate, the α-carboxylate group in N-Boc-L-Glu (OBn)-OH (4) was protected by 
treating it with CDI and 2-trimethylsilylethanol while the γ-carboxylate group was 
selectively deprotected using Pd-­‐C to give 5 in 88% yield. The N-Boc group was also 
deprotected using TsOH to give α-(2-TMS-ethyl) glutamate 6 in 51% yield. Finally, 3 
was treated with 1.5 equiv. of 6 and N-methyl-1,5,9-triazabicyclo[4.4.0]-decene (MTBD) 
in dry DMSO to give the folate recognition moiety in 41% yield.  
 
 88 
The monopropargylated derivative of cryptophane-A was also synthesized in 12 
nonlinear steps in 3% overall yield (Scheme 3.2, 3.3 and 3.4).14  
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Scheme 3.1. 5-step synthesis of α-[2-(trimethylsilyl)ethoxy]-2-N-[2-(trimethylsilyl)- 
ethoxycarbonyl]folic acid. Figure adapted from Nomura et al.41 
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Scheme 3.2. 3-step synthesis of a cyclotriguaiacylene (CTG) unit. Figure adapted from 
Wei et al.14 
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Scheme 3.3. Synthesis of [3-propargyloxy-4-(2-iodoethoxy)phenyl]methanol (D Linker)  
and [4-(2-iodoethoxy)-3-methoxyphenyl]methanol (A Linker). Figure adapted from Wei 
et al.14 
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Scheme 3.4. Synthesis of monopropargylated derivative of cryptophane-A. Figure 
adapted from Wei et al.14 
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The azidopeptide 22 was synthesized by standard solid-phase synthesis using 
Fmoc-substituted reagents.42 3-Azido propionic acid was prepared according to literature 
procedures and incorporated as the N-terminal residue. 43  The peptide 22 was synthesized 
in 85% yield and consisted of three polyethylene glycol units and lysine-arginine units to 
help solubilize the biosensor in water. The cysteine in the peptide chain was included to 
fluorescently label the biosensor for in vitro studies. The azidopeptide was orthogonally 
deprotected using 4% hydrazine in water and readily coupled to the γ-folate conjugate 7 
using coupling agents in dry DMF to yield 23 in 75% yield. In order to monitor the 
reaction, a portion of the reaction mixture was cleaved from the resin and purified by 
reverse-phase HPLC (see Experimental procedures). Once the formation of the product 
was confirmed, 23 (on solid support) was coupled to monopropargylated cryptophane-A 
to give 24 by Cu(I)-catalyzed [3+2] cycloaddition. Although the yield for 24 was initially 
low (~20% yield), it was significantly improved to approximately 80% by using a large 
excess of sodium ascorbate (40 equiv.) to ensure that copper remained reduced as Cu(I) 
to catalyze the reaction. The product was purified by reverse-phase HPLC (see 
Experimental procedures) and was determined to be readily soluble in water. To 
fluorescently label the conjugate 24, the cysteine was deprotected using TCEP and 
coupled with the maleimide functionalized Cy3 dye (excitation 550 nm and emission 575 
nm). Cy3 labeling efficiencies were determined from the ratio of dye absorbance at 550 
nm to the cryptophane absorbance at 280 nm. 25 was purified by reverse-phase HPLC 
(see Experimental procedures) and the yields at 20-30% were lower than expected. The 
removal of excess TCEP using a gel filtration column did not assist in increasing the 
yields.  
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Scheme 3.5. Synthesis of unlabeled and Cy3-labeled biosensor 24 and 25, respectively, 
where a last step involved the Cu(I)-catalyzed [3+2] cycloaddition of monopropargyl-
cryptophane to the folate-conjugated azidopeptide on solid support. 
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Figure 3.3. Cytotoxicity assays for folate-conjugated cryptophane biosensor in KB 
(blue), and HT-1080 cells (red). %Viability was determined via MTT assay after 24 h 
incubation with increasing concentrations of 24, as compared to untreated cells. 
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In order to perform cell cytoxicity and uptake studies, two cell lines were 
selected. KB cells (a cell line derived from human carcinoma of the nasopharynx) were 
selected because they are known to highly overexpress FRα while HT-1080 cells (a 
fibrosarcoma cell line) are known to underexpress FRα relative to KB cells. The 
cytotoxicity of 24 was evaluated by adding increasing concentrations (0 to 100 µM) of 
the folate-cryptophane conjugate 24 to KB (FR+) and HT-1080 (FR-) cells, as shown in 
Figure 3.3. In KB cells, the viability (scaled to 100% at 0 µM) decreased from 80% at 10 
µM to 50% at 38 µM. Maximum toxicity in KB cells (23% viability) was found when the 
cells were incubated with the highest concentration of 24 (100 µM). Cell viabilities 
determined when 0-10 µM of the biosensor was added to KB cells were comparable to 
those seen with fluorescent contrast agents such as folate-substituted poly(p-
phenyleneethynylene).44 At concentrations ~2 µM, 25 exhibited sufficient fluorescence 
intensity to be detected inside the intracellular domain both via confocal miscroscopy and 
flow cytometry and was also minimally cytotoxic. The viability of HT-1080 cells ranged 
from 100% at 0 µM to 82% at 100 µM of 24. The higher viability of HT-1080 cells 
indicates minimal toxicity in human cell lines that do not overexpress FRα. In general, 24 
was more cytotoxic to cancer cells that are FR+ than those that are FR-. This is likely due 
to the higher levels of FRα that are expressed on KB cells versus HT-1080 cells, which in 
turn causes increased intracellular accumulation of biosensor 24. Similar trends were seen 
in a previous study where a cyclic RGD peptide-conjugated cryptophane was determined 
to be more toxic in cell lines overexpressing the targeted αvβ3 integrin receptors (60% 
toxicity in ASPC-1 cells versus 30% toxicity in HFL-1 cells) after 24 h incubation at 100 
µM concentration.  
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Figure 3.4. Uptake of 4 µM Cy3-labeled 25 targeting FRα in KB (a), HeLa (b), and HT-
1080 (c) cells after 4 h incubation at 37 °C in folic acid depleted media; (d, e, f) Uptake 
of 25 was successfully blocked in the KB, HeLa and HT-1080 cell lines, respectively, 
when they were incubated in media containing folic acid.  
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In order to determine whether 25 could be selectively delivered to FR+ cells, 
confocal laser scanning microscopy (CLSM) was performed as shown in Figure 3.4.  
After 4 h incubation with Cy3-labeled 25, fluorescence was seen evenly distributed in the 
perinuclear region of KB cells as expected for receptor-mediated endocytosis (Figure 
3.4a). This is desirable as nuclear internalization of imaging agents can cause potential 
mutagenic effects on healthy cells.  Cell uptake of Cy3-labeled 25 in HeLa cells was also 
confirmed by CLSM after 4 h incubation (Figure 3.4b). The fluorescence intensity was 
lower in HeLa cells which was expected due to the highest overexpression of FRα in KB 
cells, followed by HeLa and HT-1080 cells. Uptake of 25 was even lower in HT-1080 
(FR-) cells, thereby indicating that biosensor 25 was able to discriminate between FR+ 
and FR- cells (Figure 3.4c). To analyze whether the uptake of 25 was facilitated by folate 
receptor-mediated endocytosis, 25 was co-incubated with folic acid rich medium in both 
KB, HeLa, and HT-1080 cells. Because folic acid is known to have a very high affinity 
for FRα, it was expected to outcompete 25, thereby blocking uptake. The reduction in 
fluorescence in Figures 4d-4f indicates that the folic acid did in fact inhibit uptake of 25 
and 25 was specifically recognized by the FR receptor. Indeed, the folate recognition 
moiety subunit was critical for cellular uptake of the biosensor.  
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Figure 3.5. Monitoring the accumulation of 4 µM Cy3-labeled 25 in (a) HT-1080 (FR-, 
blue) and (b) KB (FR+, red) cells using flow cytometry. Inhibition of uptake with free 
folic acid in the medium was indicated in (a) HT-1080 cells (black) and (b) KB cells 
(black).  
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In an effort to quantify the selective cellular internalization of 25 in KB and HT-
1080 cells, flow cytometry was performed. After 4 h incubation in both KB and HT-1080 
cells, there was a dramatic increase in cell-associated fluorescence. When biosensor 25 
was co-incubated with excess folic acid, the increase in median fluorescence intensity 
was much lower than when folic acid was absent. This was in agreement with the results 
from the CLSM studies, where uptake was significantly lowered when excess folic acid 
was present. In the absence of folic acid, the median cell-associated fluorescence 
intensity was approximately 45-fold higher in KB cells and 2.5-fold higher in HT-1080 
cells. Therefore, it was determined that the median fluorescence intensity in KB cells was 
approximately 10-fold higher than in HT-1080 cells. This was expected because KB cells 
are known to overexpress FRα compared to HT-1080 cells,45,46_ENREF_42 and shows 
that biosensor 25 was able to selectively target cancer cells overexpressing the intended 
receptors. 
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 Figure 3.6. Hyperpolarized 129Xe NMR spectrum of 60 µM 24 in acetate buffer at pH 
5.0  (40 scans; S/N ≈30:1 at 50 Hz line broadening) 
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Hyperpolarized 129Xe NMR spectrum of 24 was performed at 60 µM in both PBS 
buffer at pH 7.5 and acetate buffer at pH 5.0 using a 10 mm probe and a BURP pulse. 
Figure 3.6 shows 129Xe NMR chemical shifts of 64.91 and 66.11 ppm due to the presence 
of the two diastereomers for biosensor 24. This was due to the chirality of the three 
components, folate, peptide and cryptophane-A (LLL and LLR). Cryptophane-A is a 
chiral molecule and the racemic mixture of enantiomers encapsulating xenon has been 
reported to give rise to a single NMR resonance.47 However, upon conjugation of chiral 
moieties to this racemic mixture of cryptophanes, diastereomers are formed. Previous 
examples of xenon biosensors that contain multiple diastereometers include the biotin-
conjugated cryptophane developed by Spence et al.10 The biosensor consisted of four 
diastereomers due to the chiral cryptophane-A, L-amino acids, and maleimide center 
formed when the biotin was conjugated to the rest of the biosensor (RLR, RLL, LLR, 
LLL).10 This resulted in 4 distinct peaks in the 129Xe NMR spectrum. Similarly, the 
enzyme-responsive MMP-7 biosensor developed in our lab also indicated the presence of 
two diastereomers that were separated by 0.6 ppm. This was due to the chirality of the 
two components, peptide and cryptophane-A (RL and LL).14,47,48 Carbonic anhydrase 
targeting cryptophane biosensors also developed in our lab are hypothesized to form 
diastereomers when the two enantiomers that make up the biosensor interact with the 
chiral protein surface.15,49 Since for multiplexing purposes it would be preferable to only 
have single NMR resonances for biosensors targeting different biomarkers, the synthesis 
of enantiomerically pure cryptophanes is currently underway in our lab and will be 
discussed in further detail in Chapter 5. 
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129Xe NMR experiments were also performed with 24 and folate binding protein 
(FBP) to determine the change in the chemical shift upon binding to the protein. FBP is 
an expensive membrane-bound protein and is known to aggregate at low micromolar 
concentrations.50 Specifically, the MW of the monomeric protein is 29,000 Da and 
increases to approximately 300,000 Da during aggregation.50 Although it would have 
been desirable to perform the 129Xe NMR experiments at nanomolar concentrations, due 
to the sensitivity limitations of our system, micromolar concentrations had to be used. To 
minimize aggregation, all the NMR experiments were carried out at pH 5.0 in acetate 
buffer as it is known that the protein experiences lower aggregation in this buffer than at 
pH 7.0.50,51 In the first trial, 30 µM FBP was mixed with 60 µM of the biosensor. 
Although the spectrum indicated the presence of the cryptophane peak, there was no new 
peak indicating that the biosensor was bound to FBP. In a second trial, the sample was 
allowed to equilibrate for 30 min and vortexed to ensure good mixing. The results were 
similar to those of trial 1 where no distinct bound signal was observed. In a third trial, a 
lower concentration of biosensor (30 µM) was mixed in an NMR tube with 30 µM FBP 
but again no new bound peak was observed, only dilution of the free cryptophane peak. 
Additionally, 10% glycerol was added to the buffer for all 129Xe NMR experiments to 
prevent foaming and stabilize the protein. The lack of a cryptophane bound peak could be 
due to several reasons: a) protein aggregation that prevents folate binding,50 b) when 
cryptophane associates with FBP, Xe is unable to gain access, and c) the cryptophane 
itself may preclude the folate recognition moiety from binding to the protein. All these 
reasons would lead to a loss in the 129Xe bound signal. Our lab’s improving capabilities in 
hyperpolarized 129Xe NMR spectroscopy will soon make it possible to perform these 
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measurements in live cells, which will help to troubleshoot the potential problems 
outlined above. 
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CONCLUSION 
 
In summary, a novel water-soluble folate-conjugated cryptophane biosensor was 
synthesized and characterized. The folate moiety had been selectively protected to ensure 
that only the α-carboxylate group was available to bind to FRα. Confocal imaging with 
KB (FR+) and HT-1080 (FR-) cells indicated the selective uptake of the biosensor via 
folate receptor-mediated endocytosis into cells overexpressing FRα. Flow cytometry 
analysis indicated that uptake was 45-fold higher in KB cells and 2.5-fold higher in HT-
1080 cells than when competing excess folate was in solution. Also, the median 
fluorescence intensity was approximately 10-fold higher in KB cells than in HT-1080 
cells, which motivates the use of this folate-conjugated cryptophane for in vivo 
biosensing in cells overexpressing FRα. Cytotoxicity assays indicated that in the relevant 
ranges required for confocal and flow cytometry analysis (0-10 µM), the viability was 
greater than 80% in both cells lines.  129Xe NMR spectroscopy as well cellular 
spectroscopy studies that can be performed using low concentration of proteins and cells 
are currently underway and will be discussed in Chapter 5. 
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EXPERIMENTAL PROCEDURES 
Reagents 
Sigma-Aldrich: Dimethyl sulfoxide (DMSO), dimethylformamide (DMF), folate binding 
protein (FBP), folic acid, methanol, triisopropylsilane (TIS), 2,6-lutidine, piperidine, 3-
(4,5- dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT);  
Fisher: sodium chloride, copper(II) sulfate, trifluoroacetic acid (TFA), diethyl ether 
(Et2O), glutathione 
Alfa Aesar: Cesium carbonate, L-glutathione 
Novabiochem: 2-(1H-benzotriazole-1-yl) 1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU), N-Hydroxybenzotriazole (HOBt), N-methylmorpholine 
(0.4 M), Fmoc-15-amino-4,7,10,13 tetraoxapentadecanoic acid ((PEG)3), Rink amide 
resin, Fmoc-protected amino acids including Fmoc-L-Lys(ivDde)-OH, Fmoc-L-
Lys(Boc)-OH, Fmoc-L-Arg(Pbf)-OH, Fmoc-Cys(tButhio)-OH, N-methylmorpholine (0.4 
M) 
GE Healthcare: Cy3 monoreactive dye pack 
Calbiochem: Tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl) 
Invitrogen: RPMI-1640 medium, folate-depleted RPMI-1640 medium, Dulbecco’s 
phosphate buffered saline (DPBS) 
 
For biological assays, all solutions were prepared using deionized water purified by Mar 
Cor Premium grade Mixed Bed Service Deionization.  
 
 107 
General Methods.  All organic reactions were carried out under nitrogen atmosphere.  
1H NMR (500.14 MHz) and 13C NMR (125.77 MHz) spectra were obtained on a Bruker 
AMX 500 spectrometer at the University of Pennsylvania NMR facility. Electrospray 
ionization (ESI) mass spectrometry was performed in low-resolution mode on a 
Micromass LC Platform and in high resolution mode on a Micromass Autospec while 
matrix-assisted laser desorption/ionization spectrometry (MALDI) was performed on a 
Bruker Daltonic Ultraflex III MALDI-TOF-TOF at the Mass Spectrometry Center in the 
Chemistry Department at the University of Pennsylvania. Column chromatography was 
performed using 60 Å porosity, 40-75 µm particle size silica gel from Sorbent 
Technologies. Thin layer chromatography (TLC) was performed using silica gel plates 
with UV light at 254 nm for detection. HPLC analysis was performed on an Agilent 1100 
system equipped with a quaternary pump and diode array detector using a Varian 
Microsorb-MV 300-5 C8 column (4.6 × 250 mm, 5 µm). The gradient eluent was 
composed of two solvents: 0.1% aqueous TFA (solvent A) and a 0.1% solution of TFA in 
CH3CN (solvent B). UV-visible spectra were measured using a diode-array Agilent 
89090A spectrophotometer.  
 
Synthesis of 22.  Peptide 22 (Scheme 3.5) was prepared by solid-phase synthesis using 
standard Fmoc amino acid protection chemistry on Rink Amide resin (0.1 mmol scale). 
Couplings of Fmoc-protected amino acids to the resin were carried out with HBTU and 
N-methylmorpholine to generate the activated ester. The resin was swelled in DMF (10 
min) prior to synthesis. Amino acids were then added sequentially until 3-azidopropionic 
acid was attached at the N-terminus as the final step. All residues were coupled onto resin 
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by the following procedure: removal of Fmoc group (20% piperidine solution in DMF, 2 
× 5 min), wash (DMF, 6 × 30 s), activation (amino acid/HBTU/N-methylmorpholine, 1 × 
30 s) coupling (amino acid/HBTU/N-methylmorpholine, 1 × 60 min), rinse (DMF, 3 × 30 
s). The peptide was swelled in DMF for 10 min and the orthogonal lysine was 
deprotected by washing the resin five times with 4% hydrazine in DMF. The resin was 
dried and the peptide was cleaved using a mixture of TFA, TIS, and water (90/5/5) at rt 
for 4 h. The reaction mixture was filtered using a peptide vessel, concentrated and the 
peptide was precipitated by the addition of ether. The cleavage cocktail removed side 
chain protecting groups from all amino acids except for the t-butylthiol-protected 
cysteine. Semi-preparative HPLC purification of 22 was accomplished using the 
following gradient: time 0, A/B = 95/5; 0-45 min, linear increase to A/B = 50/50; 45-47 
min, linear increase to A/B = 20/80; 47-56 min, linear change to A/B = 20/80; 56-57 min, 
linear increase to A/B =95/5; 57-72 min, linear change to A/B = 95/5. MALDI MS 
calculated for peptide 22, C72H141N31O16S2 (M + H+) 1761.06; found 1760.91. 
 
Synthesis of 7. α-[2-(Trimethylsilyl)ethoxy]-2-N-[2-(trimethylsilyl)-ethoxycarbonyl]folic 
acid (7) was prepared according to literature procedure41 and matched the reported 
physical constants and NMR spectra. 
 
Synthesis of 21. Monopropargyl cryptophane was prepared according to literature 
procedure14 and matched the reported physical constants and NMR spectra. 
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Synthesis of 23. Peptide 22 on the Sieber Amide resin (30 mg, maximum 0.0201 mmol 
azidopeptide, 1 equiv.) was allowed to swell in DMF (500 µL) in a 10 mL peptide vessel 
for 10 min. The solution was filtered and 1 mL of 4% hydrazine in DMF was added to 
deprotect the ivDde group on the orthogonally protected lysine. This was repeated 5 
times and the absorption of the filtrate at 290 nm was monitored using a UV-vis spectrum 
to ensure that the deprotection had taken place. The resin was then was dried under 
vacuum. 22 was then added to a mixture of 7 (0.0402 mmol, 2 equiv.), HBTU (0.0603 
mmol, 3 equiv.), HOBt (0.0905 mmol, 4.5 equiv.), DIEA (0.1206 mmol, 6 equiv.) in dry 
DMF. The reaction was stirred overnight at room temperature under nitrogen. Once the 
reaction was complete, the resin was carefully transferred to a fritted reaction vessel and 
washed sequentially with DMF, CH2Cl2, MeOH, 1:1 MeOH/CH2Cl2 and MeOH before 
drying under vacuum. The peptide coupled to folate 23 was cleaved from the resin using 
a mixture of TFA, TIS, and water (90/5/5) at rt for 4 h. The reaction mixture was filtered 
using a peptide vessel, concentrated and the peptide was precipitated by the addition of 
ether. The cleavage cocktail removed side chain protecting groups from all amino acids 
except for the t-butylthiol-protected cysteine. Semi-preparative HPLC purification of 23 
was accomplished using the following gradient: time 0, A/B = 95/5; 0-45 min, linear 
increase to A/B = 50/50; 45-47 min, linear increase to A/B = 20/80; 47-56 min, linear 
change to A/B = 20/80; 56-57 min, linear increase to A/B =95/5; 57-72 min, linear 
change to A/B = 95/5. MALDI MS calculated for peptide-folate conjugate 23, 
C91H158N38O21S2 (M + H+) 2184.19; found 2184.05. 
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Synthesis of 24. Monopropargylated cryptophane (20 mg, 0.02186 mmol, 2 equiv.) in 
900 µL dry DMSO was added to 23 (18.2 mg on solid support, maximum 0.01093 mmol 
azidopeptide, 1 equiv.) and allowed to stir for 10 min. 2,6-lutidine (0.0219 mmol, 1 
equiv.) was added and the reaction mixture was degassed. Sodium ascorbate (0.4372 
mmol, 40 equiv.) was added dropwise, the mixture was degassed and finally an aqueous 
solution of copper(II) sulfate (0.0054 mmol, 0.5 equiv.) was added. The suspension was 
degassed with N2 and stirred at rt for 24 h. The resin was then carefully transferred to a 
fritted reaction vessel and washed sequentially with CH2Cl2, MeOH, water, and 1:1 
MeOH/CH2Cl2 before drying under vacuum. The [3+ 2] cycloaddition reaction between 
the azide-terminated folate-peptide 23 and monopropargylated cryptophane generated the 
folate-peptide-cryptophane conjugate 24 which was cleaved from the resin using a 
mixture of TFA, TIS, and water (90/5/5) at rt for 4 h. The reaction mixture was filtered 
using a peptide vessel, concentrated, and the peptide was precipitated by the addition of 
ether. The cleavage cocktail removed side chain protecting groups from all amino acids 
except for the t-butylthiol-protected cysteine. Semi-preparative HPLC purification of 24 
was accomplished using the following gradient: time 0, A/B = 95/5; 0-65 min, linear 
increase to A/B = 30/70; 65-68 min, linear increase to A/B = 20/80; 68-70 min, linear 
increase to A/B = 5/95. MALDI MS calculated for 24, C147H211N38O32S2 (M + H+) 
3102.61; found 3103.08. 
 
Synthesis of 25.  Cys-protected folate-peptide-cryptophane conjugate 24 was dissolved 
in PBS buffer (100 mM, pH 7.1) at a concentration of 60 µM. The GE protocol was 
followed to deprotect the t-butylthiol group and label the cysteine with the Cy3-
maleimide construct. TCEP (0.0006 mmol, 10 equiv.) was added to a 1 mL PBS solution 
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containing 24 and degassed. The solution was stirred for 40 min to which was added Cy3 
dye dissolved in 50 µL dry DMSO. The reaction was degassed and stirred under nitrogen 
at rt for 16 h. The reaction mixture was purified by HPLC using the following gradient: 
For Cy3-labeled 25: time 0, A/B = 95/5; 0-65 min, linear increase to A/B = 30/70; 65-68 
min, linear change to A/B = 20/80; 68-70 min, A/B = 5/95. MALDI MS calculated for 
C180H253N42O42S3 (Cy3-I) (M+ H+) 3771.81; found 3771.59. Extinction coefficients used 
to determine solution concentrations of Cy3-labeled 25 was ε280 38,000 M-1 cm-1 and ε552 
150,000 M-1 cm-1 in water. 
 
Cell Culture.  KB, HeLa and HT-1080 cells were obtained from Dr. Jerry Glickson 
(University of Pennsylvania Medical School, Philadelphia, PA). All cells were grown in 
25 cm2 tissue culture flasks in RPMI-1640 with 25 mM HEPES supplemented with 
2 mM L-glutamine, 15% fetal calf serum, 100 units of penicillin, and 100 units of 
streptomycin. Cells were subcultured on a weekly basis. 
 
Cell Viability (MTT) Assay. In 96 well plates, 25,000 KB and HT-1080 cells were 
plated per well and allowed to grow overnight. A stock solution of nonfluorescently 
labeled folate-peptide-cryptophane conjugate 24 was added to wells in triplicate at final 
concentrations of 0, 2, 10, 25, 50, 75, and 100 µM and incubated for 24 h in the dark. The 
medium was aspirated and the cells were washed thrice with DPBS before being treated 
with 20 µL of MTT for 3 h. The medium was removed and DMSO was added to 
solubilize the resulting crystals. A plate reader was used to record the absorbance at 540 
nm. Absorbance readings were subtracted from the value of wells containing untreated 
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cells, and the reduction in cell growth was calculated as a percentage of control 
absorbance in the absence of any treatment. Data show the mean of at least three 
independent experiments ± SD.  
 
Cell Uptake Studies. KB, HeLa and HT-1080 cells were grown to confluence onLabTek 
8-well microscope slides with glass coverslip bottoms at a density of 50,000 cells per 
plate. The cells were grown in folate-depleted media or 24 h prior to incubation with 4 
µM solution of Cy3-labeled 25 for 4 h at 37 oC. For blocking studies, cells were grown in 
media containing folic acid for 24 h prior to incubation with 25 under the same 
conditions mentioned above. The medium was removed and the cells were washed three 
times with DPBS. Cells were visualized using an Olympus FV1000 confocal laser 
scanning microscope with 543 nm (HeNe) laser excitation and Cy3 emission filter under 
40× magnification (Olympus UApo/340 40×, 1.15 W). 
 
Flow Cytometry Experiments. KB and HT-1080 cells were seeded in T25 flasks each 
containing 106 cells and grown for 1 day in folate-depleted RPMI-1640 medium. The 
cells were incubated for 4 h with 4 µM 25 (1.3 mL/flask). For blocking studies, 4 µM 25 
was added in the presence of medium containing folic acid. The medium was aspirated 
and cells washed 3 times with 2 mL of PBS. The cells were detached using trypsin-
EDTA and centrifuged. The supernatant was aspirated and resuspended in 650 µL 10% 
FBS in Dulbecco’s PBS and immediately analyzed on a BD LSRII machine at the Flow 
Cytometry Laboratory, Abramson Cancer Center, at the University of Pennsylvania. 
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1H NMR of the folate recognition moiety (7) in d6-DMSO at 298K 
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13C NMR of the folate recognition moiety (7) in d6-DMSO at 298K 
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HPLC purification trace for compound 22 (peptide) 
 
Semi-preparative HPLC purification of 22 was accomplished using the following 
gradient at 280 nm: time 0, A/B = 95/5; 0-45 min, linear increase to A/B = 50/50; 45-47 
min, linear increase to A/B = 20/80; 47-56 min, linear change to A/B = 20/80; 56-57 min, 
linear increase to A/B =95/5; 57-72 min, linear change to A/B = 95/5. Retention time: 
27.96 min. 
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MALDI spectrum of purified compound 22 (peptide) 
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HPLC purification trace for compound 23 (peptide-folate conjugate) 
 
 
Semi-preparative HPLC purification of 23 was accomplished using the following 
gradient at 280 nm: time 0, A/B = 95/5; 0-45 min, linear increase to A/B = 50/50; 45-47 
min, linear increase to A/B = 20/80; 47-56 min, linear change to A/B = 20/80; 56-57 min, 
linear increase to A/B =95/5; 57-72 min, linear change to A/B = 95/5. Retention time: 
26.31 min. 
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MALDI spectrum for purified compound 23 (peptide-folate conjugate) 
 
 
 
 
 
 
 
 
 
 
 
 
 
21
84
.0
5
0
21
59
.0
51
0
500
1000
1500
2000
2500I
nt
en
s.
	  [a
.u
.]
1800 2000 2200 2400 2600 2800
m/z
 119 
HPLC trace for compound 24 (peptide-folate-cryptophane conjugate) 
 
 
Semi-preparative HPLC purification of 24 was accomplished using the following 
gradient at 280 nm: time 0, A/B = 95/5; 0-65 min, linear increase to A/B = 30/70; 65-68 
min, linear increase to A/B = 20/80; 68-70 min, linear increase to A/B = 5/95. Retention 
time: 18.73 min. 
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MALDI spectrum for purified compound 24 (peptide-folate-cryptophane conjugate) 
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HPLC trace for compound 25 (peptide-folate-cryptophane conjugate) 
 
 
Semi-preparative HPLC purification of 25 was accomplished using the following 
gradient at 280 and 550 nm: time 0, A/B = 95/5; 0-65 min, linear increase to A/B = 
30/70; 65-68 min, linear change to A/B = 20/80; 68-70 min, A/B = 5/95. Retention time: 
39.67 min. 
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MALDI trace for purified compound 25 (peptide-folate-cryptophane conjugate) 
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ABSTRACT 
 
A gyroscope-inspired tribenzylamine hemicryptophane provides a vehicle for 
exploring the structure and properties of multiple p-phenylene rotators within one 
molecule. The hemicryptophane was synthesized in three steps in good overall yield 
using mild conditions. Three rotator-forming linkers were cyclized to form a rigid 
cyclotriveratrylene (CTV) stator framework, which was then closed with an amine. The 
gyroscope-like molecule was characterized by 1H NMR and 13C NMR spectroscopy, and 
the structure was solved by X-ray crystallography. The rigidity of the two-component 
CTV-trismethylamine stator was investigated by 1H variable-temperature (VT) NMR 
experiments and molecular dynamics simulations. These techniques identified gyration of 
the three p-phenylene rotators on the millisecond time scale at -93 °C, with more dynamic 
but still hindered motion at room temperature (27 °C). The activation energy for the p-
phenylene rotation was determined to be ∼10 kcal mol-1. Due to the propeller 
arrangement of the p-phenylenes, their rotation is hindered but not strongly correlated. 
The compact size, simple synthetic route, and molecular motions of this gyroscope-
inspired tribenzylamine hemicryptophane make it an attractive starting point for 
controlling the direction and coupling of rotators within molecular systems. 
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INTRODUCTION 
 
Synthetic chemical systems provide means to explore complex phenomena in 
biological machines1-8 and also to create novel molecular mechanical components.9 
Designs based on macroscopic devices include brakes, gears, propellers, rachets, 
turnstiles, rotors, scissors, and most recently gyroscopes (Figure 4.1).3,10-14 These 
molecular systems have been extensively studied in solution, in solid phases, on surfaces 
and in polymers.15 One challenge in designing these systems is the required restriction of 
some molecular degrees of freedom, while allowing specific motions of targeted 
molecular components.9 Synthesis of such molecules can also be challenging.  Criteria 
for the construction of molecular gyroscopes have been identified and generally applied: 
rotary elements (rotators) are attached to a static framework (stator); steric contacts, 
internal rotation barriers, and interaction with solvent should be minimized to allow low-
friction, low-barrier rotary motion; rotating groups are isolated and/or well-separated 
from each other.  
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Figure 4.1. Examples of molecular components designed to mimic macroscopic devices: 
a) Molecular “turnstile” developed by Moore and Bedard et al., b) Metal-centered three-
spoke molecular gyroscopes developed by Gladysz et al., and c) Solid-state crystals 
developed by Garcia-Garibay et al. Figures were adapted from Skopek and Sykes et 
al.13,14 
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One challenge in designing these systems is the required restriction of some 
molecular degrees of freedom, while allowing specific motions of targeted molecular 
components.9 Synthesis of such molecules can also be challenging.  Criteria for the 
construction of molecular gyroscopes have been identified and generally applied: rotary 
elements (rotators) are attached to a static framework (stator); steric contacts, internal 
rotation barriers, and interaction with solvent should be minimized to allow low-friction, 
low-barrier rotary motion; rotating groups are isolated and/or well-separated from each 
other.  
 
To expand upon these criteria, we designed a gyroscope-inspired framework with 
cyclotriveratrylene (CTV) and trismethylamine as the 2-component stator, bridged by 
three p-phenylene rotators (Scheme 4.1). This creates a new application for CTV, which 
has been used previously for the synthesis of cryptophanes in host-guest chemistry (with 
biosensing and chiroptical properties),16-31 supramolecular assemblies, gels and organic 
microporous polymers:32 CTV provides a rigid hemicryptophane framework for the 
synthesis of a novel gyroscope-inspired molecule. Our design incorporates a novel 
combination of features: (i) efficient, high-yielding synthetic scheme, (ii) multiple, 
proximate rotators in one covalently bonded molecular system, (iii) exclusion of other 
molecules and ions from the stator interior that may impede rotator motion, and (iv) 
hindered rotators experiencing friction through exposure to solvent. 
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Scheme 4.1. Gyroscope-inspired tribenzylamine hemicryptophane (5) possesses a rigid 
stator (a and c) and three rotator groups (b). Arrows illustrate rotation but are not 
intended to suggest unidirectionality. 
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Gyroscope-inspired molecular systems have focused largely on approaching 
barrierless rotation of isolated or sequestered rotors.  One of the first examples (also 
referred to as a molecular turnstile) was synthesized by Moore and Bedard (Figure 
4.1a).33,34 The creative design included a rigid hexa(phenylacetylene) framework that 
preserved the low barrier of rotation about the 1,4-axis of the substituted p-phenylene 
moiety. Garcia-Garibay and coworkers extended these ideas in the construction of 
amphidynamic crystals,11,15,35-54 where the introduction of bulky substituents creates 
sufficient space in the lattice framework to allow near barrierless rotation of the central p-
phenylene group (Figure 4.1c). Furthermore, the p-phenylene moiety can be 
functionalized to create a dipole moment that could be used for controlling motion with 
an external electric field.11,36-38,42 Following a different approach, Gladysz and coworkers 
prepared a series of metal-centered molecular gyroscopes in which the rotator is protected 
by three-spoke structures as part of the stator (Figure 4b). The rotational dynamics of 
these gyroscopes were studied in solution and their crystal structures indicated sufficient 
free volume around the rotator to allow low-barrier rotation.9,55-59 Most recently, 
Kitagawa et al. designed a self-assembled supramolecular gyroscope where the stator is a 
heterocapsule formed by noncovalent interactions and the rotator is an encapsulated 
guest.60 
 
Herein, we report a streamlined synthesis of a gyroscope-inspired tribenzylamine 
hemicryptophane (5, Scheme 4.2) involving multiple hindered rotators, where fast 
rotation is observed by 1H NMR spectroscopy above a critical temperature. Rotations 
about the 1,4-axis of the three p-phenylene rotators encased in a rigid CTV-
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trismethylamine stator were investigated using 1H variable temperature (VT) NMR 
spectroscopy and molecular dynamics (MD) simulations.  
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Scheme 4.2. Three-step synthesis of gyroscope-inspired tribenzylamine hemicryptophane 
5. 
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RESULTS AND DISCUSSION 
 
Synthesis and X-ray crystal structure of hemicryptophane 5. In order to synthesize 
the gyroscope-inspired tribenzylamine hemicrytophane 5, the linkers (including the 
rotators) were first cyclized in the rigid CTV framework and then closed with an amine to 
form the final three-dimensional structure (Scheme 2). Reaction of commercially 
available vanillyl alcohol 1 and dibromo-p-xylene 2 gave the versatile linker 3 in 65% 
yield. Cyclization of 3 was achieved with a catalytic amount of Sc(OTf)3 in acetonitrile to 
afford the “gyroscope scaffold intermediate” 4 in 29% yield. This reaction was based on 
previous protocols where various 3,4-disubstituted benzyl alcohols were treated with 
catalytic Sc(OTf)3 to prepare CTV and cryptophane derivatives.18 Compound 4 was 
reacted with 7 N NH3 in MeOH to give 5 in 67% yield, with an overall yield of 13% for 
the three steps. Compound 5 was characterized by solution 1H NMR and 13C NMR 
spectroscopy, high-resolution mass spectrometry (using electrospray ionization method) 
and X-ray crystallography. This short synthetic scheme utilizes mild conditions and 
results in high overall yields. Moreover, this route provides ample versatility by 
increasing the number of methylene spacer units or introducing new functional groups on 
3 to form rotators with different conformations, rotation barriers, and dipole moments. 
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Figure 4.2. (a) ORTEP representations for 5 with atom labels. Hydrogen atoms are 
omitted for clarity.  (b) Space-filling side and bottom view of 5. Atom color code: C is 
gray, O is red, N is blue, and H is white. (c) Selected bond lengths (Å), angles (°) and 
dihedral angles (°) of compound 5. 
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The X-ray crystal structure of 5 indicates the three rotators adopt a propeller 
conformation (Figure 4.2a,b). 5 crystallizes in the monoclinic space group P21/c and each 
unit cell consists of four molecules with two of each enantiomer. In both enantiomers the 
p-phenylene rotators are oriented edgewise into the interior (angled away from the 
methoxy group ortho to them) with an average dihedral angle of ~ 88.1° for O-Cbenzylic-
Cphenyl-Cphenyl, ~ -68.6° for N-Cbenzylic-Cphenyl-Cinterior-phenyl and ~ 107.5° for N-Cbenzylic-
Cphenyl-Cexterior-phenyl (see Figure 4.2c). The minimal distance from the phenylic proton on 
C44 (pointing into the cage) to the plane described by the next aryl ring (C10 to C15) is 
relatively small at 3.22 Å. After the van der Waals radii for hydrogen and carbon are 
included,61 the “clearance” distance is approximately 0.32 Å. The distance from the same 
proton to the nitrogen atom was even shorter at 2.97 Å, with clearance distance of 0.22 Å 
when van der Waals radii are included, as the nitrogen is oriented into the interior with an 
average C–N–C bond angle of 114.4° (see Figure 4.2c). This propeller-shaped 
conformation with a pyramidal nitrogen atom where the lone pair is pointed into the cage 
is similar to the crystal structure of tribenzylamine, where the rigid CTV is not present.62 
It is believed that this conformation is primarily favored due to steric hindrance.62 Despite 
the propeller conformation of the rotators and the positioning of the nitrogen atom into 
the interior of the cage, rotator motion is expected given the observed clearance 
distances.  
 
Unlike some previously reported porous gyroscopes,58 which encountered barriers 
to rotation due to the intercalation of solvent molecules (or neighboring molecules in 
solid state), the small internal volume in 5 should prevent guest encapsulation. Indeed, X-
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ray crystallography indicated an empty tribenzylamine hemicryptophane, lacking solvent 
molecules. Small molecules such as helium, dihydrogen, dinitrogen and xenon were not 
observed to bind to 5 at 1 atm over a range of temperatures, 47 °C to -93 °C (see 
Experimental procedures section). Molecular dynamics simulations were also in 
agreement with the experimental findings and suggest that these small molecular species 
should be excluded from the interior (Figure 4.3).  
 
 
 
 
 
 
 
 
 
 
 
 142 
 
 
Figure 4.3. Molecular dynamics (MD) simulations were carried out in the absence (a) 
and presence (b) of the xenon atom (OPLS63 force field parameter for Xe; ε = 0.4330 kcal 
mol-1 and r = 2.20 Å) inside of 5. Using the crystal structure of 5 as the starting structure, 
a 50 ns simulation, with a time step of 0.5 fs, was performed for each case in the absence 
of solvent at 25 °C.64 The difference of the average potential energies with and without 
xenon was 0.7 kcal mol-1, suggesting that there is no energetic stabilization in the 
presence of xenon, consistent with 5 having no experimentally observed affinity for Xe. 
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Computational modeling was used to explore effects due to rotation of the p-
phenylene rotators.  GRASP65 was employed in order to investigate whether a potential 
interior cavity within 5 emerges with rotation of the rotators. With a probe radius of 1.4 
Å, only in improbable, high-energy structures (ΔE > 30 kcal mol-1, where ΔE is the 
energy relative to the X-ray structure) where the angle of each p-phenylene rotator 
increased by 90° relative to the crystal structure was a cavity identified (Figure 4.4). This 
suggests that a cavity of sufficient volume to accommodate small guest molecules is 
essentially nonexistent, thereby preventing the inclusion of small molecules that may 
hinder p-phenylene rotation.  
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Figure 4.4. Structures with different concerted orientation of the p-phenylene rotators 
(α= β = γ). Crystal structure (green), 30° (cyan), 60° (magenta), 90° (yellow), 120° 
(purple) and 150° (orange). Also the cavity volume values using GRASP are shown. For 
clarity, hydrogens are not rendered and the high-energy structures (ΔE > 29 kcal mol-1, 
where ΔE is the energy relative to the X-ray structure) are shown as thin transparent 
sticks in order to illustrate their low probability. 
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1H VT-NMR experiments with hemicryptophane 5. In order to investigate the energy 
barrier of the rotators in solution phase, we performed a 1H VT-NMR study of 5 in 
CD2Cl2 from -93 °C to 27 °C. The NMR spectra in Figure 4.5 indicate that the rotational 
rate of the p-phenylene rotators became slow on the NMR timescale as the temperature 
was decreased. At 27 °C, the four protons (labeled H2, H3, H4 and H5 in Figure 4.5a) on 
each of the three rotators were split into two doublets at 6.1 ppm (average signal from H2 
and H4) and 6.9 ppm (average signal from H3 and H5). Upon cooling, these doublets 
became broader and the energy barrier for p-phenylene rotation was estimated from 
equations (1) and (2),66 see Experimental procedures section, to be 9.2 kcal mol-1 from the 
coalescence temperature (ca. -70 °C; kcoalesce ≈ 2300 Hz). As the temperature was further 
reduced to -93 °C, a new pair of doublets of equal intensity (3 protons each) arose for 
each doublet that coalesced. This led to splitting of the doublet for H2 and H5 and also H3 
and H4, where H2 and H3 shift upfield as they are pointed into the cavity while H4 and H5 
are oriented away from the cavity. The H3-H5 splitting pattern (Figure 4.5b) evidences 
that p-phenylene rotation at -93 °C is slow on the NMR timescale, trot > 3 ms. Similar 
temperature-dependent behavior was recently reported for a 2,3-dichlorophenylene 
rotator caged within a polysilaalkane stator.67 In line with our design, the stator remained 
rigid throughout the 1H VT-NMR dataset as indicated by the fact that the integration and 
splitting pattern of all CTV-trismethylamine proton peaks were constant. It is also 
interesting to note that protons HA1 and HA2 remained diastereotopic throughout the 1H 
VT-NMR series (Figure 4.5b). All peaks were assigned by 1H-1H NOESY experiment 
(Figure 4.6) 
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Figure 4.5. (a) Schematic model of the molecular motion of 5. (b) 1H VT-NMR spectra 
of 5 measured in CD2Cl2 with a 500 MHz spectrometer.  
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Figure 4.6.  1H-1H NOESY spectrum of 5 in CDCl3 at 27 °C with 500 MHz spectrometer 
to determine the assignment of protons.  
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Molecular dynamics simulations. To investigate the conformational fluctuations of the 
rotators and stator, MD simulations were carried out on 5 (Figure 4.7). One of the crystal 
structures was used as the initial structure, and the length of the simulations was 50 ns. 
Equilibration was confirmed by monitoring relaxation of structural parameters (Figure 
4.7).  Three dihedral angles that reflect the conformations of the rotators were selected: 
(α ≡ N1-C16-C13-C14, β ≡ N1-C32-C29-C30 and γ ≡ N1-C48-C45-C44). The symmetry 
of the structure yields nearly identical average values of these angles that are in 
agreement with the values observed in the crystal structure: α = -72.3° ± 10°, β = -71.8° 
± 10° and γ = -72.8° ± 10°; the uncertainties (fluctuations) are one standard deviation 
(Figure 4.8). The MD simulations at 25 °C indicated limited fluctuations within the 
structure on the nanosecond time scale (Figure 4.9), and the CTV unit that forms the 
stator remains highly rigid, in agreement with the NMR results noted above. The p-
phenylene units are not observed to rotate and instead librate in a manner consistent with 
a hindered rotor that rotates on a time scale > 100 ns. Therefore, simulations, X-ray, and 
NMR structural data all agree that the propeller-shaped conformation is highly favored in 
5. High temperatures were artificially employed to observe rotation in the simulations: at 
527 °C, rotations of the three p-phenylenes are frequent, conformations where the 
rotators are directed edgewise into the interior (similar to what is seen in the crystal 
structure) are preferentially populated, and no preferred rotational direction in the three p-
phenylenes is observed. 
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Figure 4.7. Structural information related with the equilibration of the systems for the 
MD simulations. Plotted is the root mean square deviation (RMSD) for the entire system 
as a function of time step. All-atom MD simulations were carried out in the absence of 
solvent at 25 °C. The temperature was controlled using Langevin dynamics. The time 
step of the simulations was 0.5 fs and the length of the simulations was 50 ns.   
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Figure 4.8. Plots of the fluctuations in the dihedral angles involving the p-phenylene 
rings in one of the enantiomers of 5 as observed in the molecular dynamics simulations. 
These three dihedral angles defined as: α  ≡  N1-C16-C13-C14, β  ≡  N1-C32-C29-C30 
and γ  ≡  N1-C48-C45-C44. As mentioned in the main text, the mean and SD values are α 
= -72.3° ± 10°, β = -71.8° ± 10° and γ = -72.8° ± 10°.  
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Figure 4.9. Orthogonal views of 30 superimposed structures from the MD simulation of 
5. The dihedral angles are indicated: α (magenta), β (cyan) and γ (yellow). 
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To investigate further the p-phenylene rotation and interactions among the rotators, 
the crystal structure of 5 was minimized, and the dihedral angle α was systematically 
varied (Figure 4.10). The structure was then relaxed via energy minimization, 
constraining the coordinates of all atoms but those in the two remaining β and γ p-
phenylene rings. The β-ring is essentially invariant during the rotation. The γ-ring only 
rotates at most 19.7° to accommodate the 180° rotation of the α-ring. An energy barrier 
arises due to the steric interaction between the α-ring and γ-ring. Interestingly, the 
rotational energy barrier estimated from this simplistic and highly-constrained calculation 
(~12 kcal mol-1) is consistent with the experimental value inferred from the 1H VT-NMR 
experiments (~10 kcal mol-1). The modeling results suggest that, although not entirely 
independent, the rotations of the α- and γ-rings are only weakly coupled. 
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Figure 4.10. Minimized energy as a function of Δα, which is rotation of the α dihedral 
angle relative to the energy minimized X-ray structure (gray). The crystal structure of 5 
was minimized, and the angle α was varied in 10° increments, driving rotation of the α-
ring (magenta). For each value of Δα, the structure was energy minimized, constraining 
the coordinates of all atoms but those in the two remaining p-phenylene rotators: β-ring 
(cyan) and γ-ring (yellow). For clarity: the CTV moiety and hydrogens are not shown; 
two carbons of the α-ring are rendered black. 
 
 
 
 
 
 
 154 
CONCLUSIONS 
In summary, a novel gyroscope-inspired tribenzylamine hemicryptophane 5 was 
synthesized in three steps in good overall yield using mild conditions. This synthetic 
route offers the possibility of preparing hemicryptophanes with multiple, proximate 
rotators, where the molecular properties of the rotators can be varied by changing the 
length and composition of the linkers used to cyclize the “gyroscope scaffold 
intermediate” 4. The compact size of the cavity in this system helps to avoid the inclusion 
of solvent and gaseous molecules that have the potential to inhibit rotation. 1H VT-NMR 
data indicate a critical temperature for the onset of rotation on the sub-millisecond time 
scale and a hindered, dynamic motion of these three rotators at room temperature.  The 
desired rigidity of the CTV stator and the rotator properties of the p-phenylenes were 
corroborated by 1H VT-NMR spectroscopy and MD simulations. As a p-phenylene ring 
rotates, it encounters one of the neighboring p-phenylenes, leading to a steric barrier that 
hinders rotation. Rotation of the rings appears not to be strongly correlated with one 
another. 
 
The compact size and molecular motions of 5 make it a compelling initial motif from 
which to engineer unidirectional, potentially coupled rotators for molecular locomotion 
or transmitting torque. Towards this goal, it may be possible to introduce sterically bulky 
substituents on the linkers to control the temperatures at which rotation becomes 
accessible and to favor one direction of rotation. Different substituent groups can also be 
introduced to create a dipole moment on the rotators, thereby allowing the use of electric 
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fields to explore rapid conformational response in these systems and to control the 
direction of rotation. 
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EXPERIMENTAL PROCEDURES 
Reagents. All reactions were carried out in oven-dried glassware under an atmosphere of 
dry nitrogen. Column chromatography was performed using 60 Å porosity, 40-75 µm 
particle size silica gel from Sorbent Technologies. Thin layer chromatography (TLC) was 
performed using silica gel plates with UV light at 254 nm for detection. 1H NMR (360 
and 500 MHz) and 13C NMR (125 MHz) spectra were acquired on Bruker DMX 360 and 
AMX 500 spectrometers. Electrospray ionization (ESI) mass spectrometry was 
performed in high-resolution mode on a Micromass Autospec instrument. All reagents 
were commercially available and used without further purification, unless otherwise 
stated. 
 
[4-(4(bromomethyl)benzyl)oxy-3-methoxyphenyl]methanol (3). A mixture of vanillyl 
alcohol 1 (2.5091 g, 16.276 mmol, 1.0 equiv.), dibromo-p-xylene 2 (6.4033 g, 24.259 
mmol, 1.5 equiv.), and K2CO3 (2.2511 g, 16.288 mmol, 1.0 equiv.) dissolved in acetone 
(24.0 mL, 0.786 g/ml, 18.9 g) was heated at 70 °C overnight with stirring. The reaction 
solvent was removed by rotary evaporation. The resulting residue was rinsed in a 
separatory funnel with a 1:1 mixture of H2O (60 mL) and CH2Cl2 (60 mL). The phases 
were separated and the aqueous layer extracted three times with CH2Cl2 (100 mL). The 
combined organic layer was washed once with 1 M NaOH (100 mL) and once with 
saturated NaCl (100 mL). The organic layer was dried over MgSO4, filtered, and 
evaporated under reduced pressure. The crude material was purified by silica gel column 
chromatography (5:95 Acetone:CH2Cl2 à 20:80 Acetone:CH2Cl2) to give 3 as white 
powder  (3.5422 g, 65%): m.p. 86-88 °C; 1H NMR (500 MHz, CDCl3, 25 °C) δ = 7.42-
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7.38 (m, 4H), 6.96 (s, 1H), 6.85-6.81 (m, 2H), 5.14 (s, 2H), 4.60 (s, 2H), 4.49 (s, 2H), 
3.89 (s, 3H), 1.86 (s, 1H); 13C NMR (125 MHz, CDCl3, 25 °C) δ = 149.9, 147.6, 137.6, 
137.5, 134.5, 129.4, 127.7, 119.4, 114.1, 111.1, 70.8, 65.4, 56.1, 33.36; HRMS (ESI) 
calculated for C16H17BrO3 (M+Na+) 359.0259; found 359.0239. 
 
2,7,12-Tris-(4-bromomethylbenzyloxy)-3,8,13-trimethoxy-10,15-dihydro-5H 
tribenzo[a,d,g]cyclononene (4). A mixture of 3 (2.0232 g, 6.0210 mmol, 1.0 equiv.) and 
Sc(OTf)3 (0.0295 g, 0.0599 mmol, 0.01 equiv.) dissolved in MeCN (5.9 mL, 0.786 g/mL, 
4.7 g) was heated at 65 °C overnight with stirring. The reaction solvent was removed by 
rotary evaporation. The resulting residue was extracted twice with CH2Cl2 (150 mL) and 
washed three times with sat. NaCl (150 mL). The organic layer was dried over anhydrous 
MgSO4, filtered, and evaporated under reduced pressure. The crude material was purified 
by silica gel column chromatography (CH2Cl2 à 2:98 THF:CH2Cl2) to give 4 as white 
powder (0.5571 g, 29%): m.p. 91-93 °C; 1H NMR (360 MHz, CDCl3, 25 °C) δ = 7.39-
7.37 (m, 12H), 6.85 (s, 3H), 6.72 (s, 3H), 5.09 (s, 6H), 4.73 (d, 3H, J = 13.7 Hz), 4.50 (s, 
6H), 3.76 (s, 9H), 3.50 (d, 3H, J = 13.8 Hz); 13C NMR (125 Hz, CDCl3, 25 °C) δ = 148.6, 
147.2, 137.9, 137.5, 132.9, 131.9, 129.4, 127.6, 116.4, 114.0, 71.4, 56.4, 36.6, 33.3; 
HRMS (ESI) calculated for C48H45Br3O6 (M+) 954.0766; found 954.0724. The NMR 
spectra matched the reported literature data.68 
 
Tribenzylamine Hemicryptophane (5). A mixture of 4 (0.0406 g, 0.0426 mmol, 1.0 
equiv.) and K2CO3 (0.0869 g, 0.629 mmol, 15.0 equiv.) dissolved in MeCN (58 mL, 
0.786 g/mL, 46 g) was heated at 90 °C with stirring as 7 N NH3 in MeOH (0.0711 mL of 
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7 N NH3, 0.5 mmol, ~12 equiv., in 4.7 mL of MeCN) was added by a syringe pump over 
8 h. The reaction solvent was removed by rotary evaporation. The resulting residue was 
extracted with CH2Cl2 and transferred to a separatory funnel. The organic layer was 
washed once with a 1:1 mixture of H2O (50 mL) and 1 M NaOH (50 mL) and then with 1 
M NaOH (50 mL). The aqueous layer was extracted with CH2Cl2 (50 mL) and the 
combined organic layer was washed with sat. NaCl (50 mL). The organic layer was dried 
over anhydrous MgSO4, filtered, and evaporated under reduced pressure. The crude 
material was purified by silica gel column chromatography (50:50 CH2Cl2: hexanes à 
50:40:10 CH2Cl2: hexanes: EtOAc à 60:30:10 CH2Cl2: hexanes: EtOAc; all with 1% 
TEA) to give 5 as a white powder (0.0206g, 67%): m.p. (decom.) > 250 °C); 1H NMR 
(360 MHz, CDCl3, 25 °C) δ = 7.34 (s, 3H), 6.96-6.93 (m, 9H), 6.18 (d, 6H, J = 7.9 Hz), 
5.41 (d, 3H, J = 12.1 Hz), 5.06 (d, 3H, J = 12.2 Hz), 4.83 (d, 3H, J = 13.7 Hz), 3.60 (d, 
3H, J = 13.8 Hz), 3.58 (s, 9H), 3.54 (d, 3H, J = 13.2 Hz), 3.41 (d, 3H, J = 13.2 Hz); 13C 
NMR (125 MHz, CDCl3, 25 °C) δ = 147.7, 143.0, 140.3, 132.9, 131.7, 130.8, 128.4, 
127.4, 117.9, 113.9, 68.8, 55.5, 55.3, 34.9; HRMS (ESI) calculated for C48H45NO6 
(M+H+) 732.3326; found 732.3340.    
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Crystal growth and X-ray crystallography. Compound 5 was crystallized by vapor 
diffusion of diethyl ether or n-pentane into toluene. It crystallizes in the monoclinic space 
group P21/c (systematic absences 0k0: k = odd and h0l: l = odd) with a = 17.098(2) Å, b 
= 11.4592(9) Å, c = 21.096(2) Å, β = 113.539(2)°, V = 3789.3(6) Å3, Z = 4 and dcalc = 
1.283 g/cm3.  X-ray intensity data were collected on a Rigaku Mercury CCD area 
detector employing graphite-monochromated Mo-Kα radiation (λ = 0.71073 Å) at a 
temperature of -130 °C. Preliminary indexing was performed from a series of twelve 0.5° 
rotation images with exposures of 30 s. A total of 336 rotation images were collected 
with a crystal to detector distance of 35 mm, a 2θ swing angle of  -12°, rotation widths of 
0.5° and exposures of 10 s: scan no. 1 was a φ-scan from 170° to 338° at ω = 0° and χ = 
0°.  Rotation images were processed using CrystalClear,69 producing a listing of 
unaveraged F2 and σ(F2) values which were then passed to the CrystalStructure70 
program package for further processing and structure solution on a Dell Pentium III 
computer. A total of 15571 reflections were measured over the ranges 5.2 ≤ 2θ ≤ 50.02°, 
-16 ≤ h ≤ 20,  -13 ≤ k ≤ 12,  -23 ≤ l ≤ 25 yielding 6601 unique reflections (Rint = 0.0261). 
The intensity data were corrected for Lorentz and polarization effects and for absorption 
using REQAB71 (minimum and maximum transmission 0.853, 1.000). 
 
The structure was solved by direct methods (SIR97).7 2 Refinement was by full-
matrix least squares based on F2 using SHELXL-97.7 3 All reflections were used during 
refinement (F2 values that were experimentally negative were replaced by F2 = 0). The 
weighting scheme used was w = 1/[σ2(Fo
2 )+ 0.0547P2 + 0.9350P] where P = (Fo
2  + 2F c
2 
)/3. Non-hydrogen atoms were refined anisotropically and hydrogen atoms were refined 
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using a "riding" model.  Refinement converged to R1 = 0.0479 and wR2 = 0.1107 for 5502 
reflections for which F > 4s(F) and R1 = 0.0599, wR2 = 0.1204 and GOF = 1.078 for all 
6601 unique, non-zero reflections and 500 variables (R1 = ∑ ||Fo| - |Fc|| / ∑ |Fo|; wR2 = {∑ 
w (F o
2  - F c
2 )2 / ∑ w(F o
2 )2}1/2 ; GOF = {∑ w (F o
2  - F c
2 )2 / (n - p)}1/2 where n = the number 
of reflections and p = the number of parameters refined). The maximum Δ/σ in the final 
cycle of least squares was 0.001 and the two most prominent peaks in the final difference 
Fourier were +0.173 and -0.253 e/Å3. 
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Calculating from 1H VT-NMR data the energy barrier for p-phenylene rotation. 
Equation 1 was used to determine the p-phenylene rotation rate at the coalescence 
temperature: 
                           (1) 
where k is the rate coefficient, ∆v0 = vA-vB is the chemical shift difference (in Hz) 
between the two separate signals at slow exchange (in this case at -93 °C or 180 K). The 
Arrhenius equation (2) was used to determine the activation energy, Ea, at the 
coalescence temperature, T (in K): 
  (2) 
where A is the pre-exponential factor and R is the universal gas constant.66 
 
 
 
 
 
 
 
 
 
 
 
€ 
k = πΔv02
€ 
ln k /Hz( ) = − EaR
1
T
⎛ 
⎝ 
⎜ 
⎞ 
⎠ 
⎟ + ln A /Hz( )
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Computational methods. All-atom MD simulations were carried out using NAMD2.64 
The internal bonded parameters were obtained from AMBER-9474 and the nonbonded 
parameters were proposed in previous studies.75-79 Simulations were performed in the 
absence of solvent at 25 °C and temperature was controlled using Langevin dynamics 
with a damping coefficient of 5 ps-1. The time step of the simulations was 0.5 fs. 
Relaxation calculations using energy minimization consist of up to 10,000 steps of the 
conjugate gradient algorithm as implemented in NAMD2; energy was monitored to 
confirm minimization.64  
 
GRASP65 was employed to investigate a potential interior cavity within 5. Different 
conformations were generated by manual rotations of the three p-phenylenes. The 
rotations were systematically performed in 10° increments using one of the crystal 
structures of 5 as reference. A probe radius of 1.4 Å was used for all calculations. 
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1H NMR and 129Xe NMR experiments to determine the binding of He, H2, N2 and Xe 
to hemicryptophane 5 
To conduct NMR experiments, 0.0005 g (0.0007 mmol) of hemicryptophane was 
dissolved in 500 µL of CDCl3 or CH2Cl2 to provide a final concentration ~ 1.4 mM.  In 
order to determine encapsulation for He, H2 and N2, 1H NMR experiments were 
performed. For Xe, a hyperpolarized 129Xe NMR spectrum was collected. For detailed 
Experimental procedures for hyperpolarized 129Xe NMR spectroscopy, please refer to the 
Supporting Information in Chambers et al.19 For these NMR experiments, the 
hemicryptophane solution was loaded into a 5-mm stopcock-sealable NMR tube. The 
samples were degassed using the freeze-pump-thaw method. The gas (e.g., He, H2, N2) 
was then bubbled into the sample tube for a few minutes, sealed, shaken and allowed to 
equilibrate for 1, 3, 24 and 48 h. Hyperpolarized 129Xe NMR spectra were collected in the 
minutes following bubbling with hyperpolarized 129Xe. 
 
No evidence of binding was observed for He, H2, N2 or Xe due to the absence of 
spectral changes in the 1H and 129 Xe NMR spectra when each of these gases was 
introduced. 1H variable temperature (VT) NMR spectroscopy was also performed for He, 
H2, and N2 at temperatures ranging from -93 °C to 47 °C. None of these spectra indicated 
binding even at the lowest temperature, further confirming that these gas molecules were 
not encapsulated by the hemicryptophane. 
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  1H NMR of 3 in CDCl3 at 25 °C 
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13C NMR of 3 in CDCl3 at 25 °C 
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       1H NMR of 4 in CDCl3 at 25 °C 
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          13C NMR of 4 in CDCl3 at 25 °C  
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       1H NMR of 5 in CDCl3 at 25 °C 
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          13C NMR of 5 in CDCl3 at 25 °C 
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CHAPTER 5: SUMMARY AND FUTURE DIRECTIONS 
 
 
This thesis aimed to look at the role of cryptophanes and their derivatives in host-
guest chemistry (Chapter 2), 129Xe NMR biosensing for early cancer detection (Chapter 
3), and the emerging field of molecular devices (Chapter 4). 
 
Chapter 2 focused on the development of a new water-soluble tris-
(triazole)ethylamine cryptophane (TTEC) and its binding affinity for two noble gases: 
xenon and radon. TTEC was determined to be the tightest xenon binder to date (KA = 
42,000 M-1 at 293 K in buffer). Preliminary computational studies by Lu Gao in the 
Saven lab predict that TTEC should have the strongest binding affinity for xenon, at least 
in part because it has the lowest occupancy of water molecules inside the cavity (~0.5) 
when compared to other anionic cryptophanes (e.g., Huber’s hexaacid cryptophanes,1 
TAAC,2 and TTPC).3 Additionally, simulations showed that the other anionic 
cryptophanes had a higher population of sodium counter ions around them than TTEC. 
Since xenon binding requires interior water molecules and solvent cations to be 
displaced, this lower occupancy of both encourages tighter binding.  TTEC also 
represents the first example of a discrete molecular species binding to radon. The 
radiometric binding assay developed is extremely versatile and can be used in future 
studies to determine the binding affinity of a wide variety of water-soluble hosts to radon. 
Since indoor accumulation of radon may cause a 5-31% increase in lung cancer risk per 
100 Bq m-3 exposure,4 it is important to understand how radon binding to specific 
biological molecules  may lead to a higher incidence of cancer. 
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The promising diagnostic applications of 129Xe gas as a sensitive MRI contrast 
agent (outlined in Chapters 1 and 3) make the development of tighter xenon binders an 
important goal. Future studies could include the synthesis of water-soluble cryptophane-
A or cryptophane-1.1.1. derivatives where anionic and cationic functional groups could 
be incorporated at varying distances from the cryptophane core. Because a cationic 
water-soluble cryptophane (TTEC) shows the highest affinity for xenon to date, this 
suggests that improved Xe binding may come from incorporating cationic amine groups 
closer to the cryptophane core (e.g., as in TAAC) or in a smaller host (e.g., cryptophane 
1.1.1.).  We have shown that the peripheral solubilizing groups can alter the entropic and 
enthalpic contributions along with the overall binding affinity of the host towards xenon. 
The kinetics of xenon binding are also extremely important for applications involving 
ultra-sensitive hyperpolarized 129Xe detection. These studies will be guided by 
computational calculations in collaboration with the Saven lab, and include 
considerations of cryptophane solvation, as well as interactions with cations and anions in 
solution. Moreover, we anticipate that generating related host molecules with larger 
dipole moments will lead to much higher xenon affinities. This was one motivation for 
the generation of hemicryptophanes that incorporate an electron-donating amine. The 
first-generation hemicryptophane of this type synthesized by our laboratory was too small 
and rigid to bind Xe but had other favorable physical properties, as described in Chapter 
4. 
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The synthesis of cryptophanes with high binding affinities for xenon plays a 
central role in our lab’s overall goal to develop 129Xe biosensors for early cancer 
detection (outlined in Chapter 3). A folate-conjugated xenon biosensor was developed in 
this thesis, which was readily soluble in water and was successfully delivered to cells 
overexpressing FRα. The biosensor showed a 10-fold selectivity for KB cells that 
overexpressed FRα, which is currently the highest level of selectivity reported by a 
cryptophane biosensor in vitro.  
 
In an effort to synthesize a cocktail of biosensors that target a variety of medically 
relevant biomarkers for multiplexing purposes, integrin αvβ3-targeting cryptophane 
biosensors have been developed in our laboratory by Garry Seward.5,6 Integrin αvβ3 is an 
important biomarker as it has been shown to be associated with tumor angiogenesis and 
metastasis7,8 and similar to the folate receptor, it is overexpressed in a large variety of 
tumor cells whereas expression is minimal in most normal tissues.9-11 To target the 
integrin αvβ3 receptors, the cryptophane was conjugated to a cyclic arginine–glycine–
aspartic acid (RGD) moiety by a Huisgen [3+2] cycloaddition reaction. Additionally, to 
overcome solubility issues, two propionic acid groups were added to the two remaining 
propargyl groups on the cryptophane (Figure 5.1).5 The biosensor was successfully 
delivered into cells and showed a 4-fold selectivity by flow cytometry towards cells 
overexpressing the targeted receptor. 129Xe NMR spectroscopy studies were performed 
and the biosensor indicated a shift of 4 ppm upon binding to the targeted protein.5 
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Figure 5.1. a) Chemical structure of the c[RGDyK]-labeled cryptophane biosensor, b) 
Uptake of 1 µM Alexa Fluor 488-labeled c[RGDyK]-cryptophane targeting AsPC-1 cells 
(A–D) and HFL-1 cells (E–H); (A, E). Targeting of cryptophane was relatively 
unaffected by coincubation with 10 mM c[RADfK] (B, F).  However, uptake was 
blocked by co-treatment with 10 mM c[RGDyK] peptide (C, G) and 10 mM anti-av 
antibody (D, H), c) Hyperpolarized 129Xe NMR spectra of i) biosensor alone (129Xe NMR 
chemical shift at 65.8 ppm), ii) biosensor binding to αIIbβ3 integrin; the ‘‘free’’ biosensor 
gave a 129Xe NMR chemical shift at 67.1 ppm, which was shifted 1.3 ppm downfield 
from ‘‘free’’ biosensor due to addition of glycerol while the ‘bound’’ biosensor appeared 
at 71.2 ppm, representing a 4.1 ppm downfield shift, iii) blocked by c[RGDyK]; ‘‘free’’ 
biosensor at the same 129Xe NMR chemical shift, but no ‘‘bound’’ biosensor was 
detected. Adapted from Seward et al.5 
A particular focus of our lab has been the design of xenon
biosensors for the early and accurate diagnosis of cancer.21
Towards this goal, cryptophane biosensors targeting matrix
metalloproteinase, carbonic anhydrase, and integrin cancer
biomarkers were previously synthesized.12,16,22,23 The current
study provides strong evidence that cryptophane–peptide
conjugates can be targeted specifically to cells that overexpress
the avb3 integrin receptor. Integrin avb3 is a heterodimeric cell
adhesion protein that has been linked to both tumor angiogenesis
and metastasis.24,25 The avb3 integrin receptor is also known to be
highly up-regulated in a wide range of fast growing tumor cells,
compared to minimal expression in most normal tissues, making
it a broad spectrum tumor marker.26–28 Peptides containing
arginine–glycine–aspartic acid (RGD) sequences are known to
bind the integrin receptor with high affinity (IC50 ¼ 29 nM
against 125I-echistatin, an RGD-containing snake venom
peptide).29–32 Probes containing multimeric or monomeric RGD
peptides have been used to image avb3 integrin receptor expres-
sion by fluorescence,33 MRI,28,34 and nuclear imaging tech-
niques.35,36 In our previous study, cryptophane was targeted to
cell surface integrin receptors by conjugation to a linear (RGD)4
peptide.23 The cryptophane–(RGD)4 conjugate exhibited limited
water solubility, likely due to intermolecular electrostatic inter-
actions and hydrogen bonding between arginine and aspartic
acid residues. This necessitated use of 10% dimethyl sulfoxide for
water solubilization, and limited the range of analytical and cell
characterization studies that could be performed with the cryp-
tophane–(RGD)4 biosensor.
23
Herein we describe the use of a cyclic targeting peptide,
c[RGDyK], to deliver cryptophane specifically to cells expressing
avb3 integrin receptor. While the linear RGD tetra repeat effec-
tively binds integrin receptors, cyclic RGD peptides are known to
target avb3 integrin receptors with approximately 10-fold higher
affinity.33 By employing a peptide ligand with higher binding
affinity, the cryptophane biosensor was more effectively deliv-
ered to avb3 integrin-expressing cells. The c[RGDyK]-labeled
cryptophane was further modified to improve water solubility
and allow detection of integrin receptor by hyperpolarized
129Xe NMR spectroscopy.
Results and discussion
Synthesis of cryptophane biosensors
The synthesis of cryptophane biosensor 3 is shown in Scheme 1.
Tripropargylated cryptophane 1 was synthesized as previously
reported with yields of 2–4%.11,16 The amine of the lysine side
chain in the c[RGDyK] peptide was converted to azidopeptide 2
in greater than 95% yield by overnight reaction with triflyl azide
in water, CH2Cl2 and methanol (1 : 1 : 1).
37 The azidopeptide
was then reacted with 1 by a copper(I)-catalyzed [3 + 2] azide–
alkyne Huisgen cycloaddition in 80–89% yield38–41 and the
product was purified by reverse-phase HPLC. HPLC purification
indicated the presence of two side-products that correspond to
cryptophane conjugated to two or three peptides. These adducts
were readily separated from biosensor 3 during HPLC purifica-
tion, allowing isolation of the desired mono-functionalized
product.
Biosensor 3 required addition of 150 mMNaCl to be dissolved
in aqueous solution, suggesting aggregation due to an interaction
between the charged residues of the c[RGDyK] peptide.
Evidence of aggregation was seen at concentrations of 3 as low as
120 mM by UV-vis spectroscopy. For 129Xe NMR studies, two
azidopropionic acids were reacted in 80% yield with the
remaining propargyl moieties of 3 to generate biosensor 5.
Biosensor 5 was soluble in pure water at concentrations of up to
250 mM, indicating a substantial improvement in water
solubility.
In vitro competitive binding assay
The binding of biosensor 3 was ass ssed by in vi ro competitive
binding assays (Scheme 2) against aIIbb3, avb3 and avb5 integrin
receptors to investigate cell receptor targeting. The resulting IC50
values are shown in Table 1. IC50 values for cyclic RAD and
RGD peptides are comparable to previously reported values for
these peptides binding integrins assayed by this method.42,43
When the inhibition of vitronectin binding to immobilized avb3
integrin receptor was examined, the IC50 value for biosensor 3
was found to be 32 nM. Compared to the c[RGDyK] peptide
alone, which had an IC50 of 8 nM, biosensor 3 bound with
approximately 4-fold lower affinity.
Inhibition of fibrinogen binding to aIIbb3 was also measured
for 3 and the IC50 value was found to be 18 nM. This reflects
approximately 10-fold weaker binding for this receptor
compared to the c[RGDyK] peptide (IC50¼ 1.6 nM). IC50 values
for both aIIbb3 and avb3 integrin proteins represent tight
binding and should allow for receptor targeting during in vitro
experiments.
Binding was also assessed for avb5 integrin receptor as it is
sometimes co-expressed in tumors and can contribute to angio-
genesis but is not known to bind RGD motifs.43,44 Notably little
Scheme 1 Synthesis of c[RGDyK]-labeled cryptophane biosensors.
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binding was observed in these binding assays. The c[RGDyK]
peptide bound with an IC50 of 200 nM, while the biosensor
bound with IC50 of 700 nM, indicating a high degree of specificity
of biosensor 3 for avb3 integrin receptors.
Viability studies
Cell viability for 3 was measured by MTT assays in NCI-H1975
lung carcinoma cells, AsPC-1 pancreatic carcinoma and HFL-1
lung fibroblasts after 24 h exposure to increasing concentrations
of 3, as shown in Fig. 1. Viability was reduced by 50% at
a cryptophane concentration between 75 and 100 mM in AsPC-1
and NCI-H1975 cell cultures. The biosensor showed lowest
toxicity in the HFL-1 cell line. A 50% reduction in viability was
not observed in HFL-1 fibroblasts, indicating minimal toxicity in
normal human cells at the concentrations of interest for per-
forming 129Xe NMR biosensing experiments. Increased cyto-
toxicity in AsPC-1 and NCI-H1975 cell cultures was likely due to
higher expression levels of avb3 integrin receptors in cancer cell
lines,29,30 leading to increased cellular uptake of cryptophane.
Maximum toxicity was found to be 61% in AsPC-1 and 57% in
NCI-H1975 cells with 100 mM biosensor 3. These toxicity values
are in agreement with previously measured cell-permeable
cryptophanes.23 In a previous study we found that when a linear
RGD peptide was attached to cryptophane and tested n cells,
maximum toxicity was in the range of 30–40% in both cancerous
and non-cancerous cells after 24 h incubation at 100 mM
concentration.23 Biosensor 3 was similarly toxic in the non-
cancerous HFL-1 fibroblasts, reaching a maximum toxicity of
40% after 24 h incubation at 100 mM concentration.
Cellular uptake
Uptake of Alexa Fluor 488-labeled c[RGDyK]-cryptophane 4 by
cells was monitored by confocal laser scanning microscopy
(Fig. 2). Incubation of AsPC-1 (Fig. 2A) and HFL-1 (Fig. 2E)
cells with 4 (1 mM) for 1 h gave bright fluorescence throughout
the cell interior. When cells were co-incubated with 4 and
a 10-fold excess of c[RADfK] peptide (which is known to be
a weak binder of the avb3 integrin receptor), levels of fluorescence
remained throughout the cell interior (Fig. 2B and 2F). From
confocal images, cellular fluorescence was observed to decrease
significantly when 4 was co-incubated with a 10-fold excess of
either c[RGDyK] peptide (Fig. 2C and 2G) or anti-av antibody
(Fig. 2D and 2H), both of which target avb3 integrin receptor
with high affinity. Both the antibody and peptide control blocked
cryptophane biosensor binding and inhibited receptor-mediated
Scheme 2 In vitro integrin competitive binding assay. One of three
integrin proteins (avb3, aIIbb3, avb5) was coated on a 96 well plate with
overnight incubation. Biotinylated natural ligands (red circles) and
c[RGDyK]-labeled cryptophane 3 (competitive binder, blue circles) were
added to the integrin and incubated for 3 h. Unbound compounds were
removed with gentle washing and NeutrAvidin–HRP was added to each
well. Bound NeutrAvidin–HRP was then quantified using tetramethyl
benzidine horseradish peroxidase substrate.
Fig. 1 Viability of AsPC-1 (blue), HFL-1 (red) and NCI-H1975 (yellow)
cells after treatment with increasing concentrations of c[RGDyK]-labeled
cryptophane 3. % Viability was measured by MTT assay after 24 h
incubation with increasing concentrations of 3 as compared with
untreated cells.
Fig. 2 Uptake of 1 mM Alexa Fluor 488-labeled c[RGDyK]-crypto-
phane 4 targeting AsPC-1 cells (A–D) and HFL-1 cells (E–H). Micro-
graphs show 4 uptaken by cells after 1 h incubation (A, E). Targeting of 4
was relatively unaffected by co-incubation with 10 mM c[RADfK] (B, F).
However, uptake of 4 was blocked by co-treatment with 10 mM
c[RGDyK] peptide (C, G) and 0.15 mg mL!1 anti-av antibody (D, H).
Table 1 IC50 values for biosensor 3 and peptide controls
avb3
IC50 (nM)
avb5aIIbb3
Biosensor 3 31.6 " 2.1 18.1 " 2.4 700
c[RADfK] >5000 >1000 >10 000
c[RGDyK] 8.2 " 2.0 1.6 " 0.6 200
This journal is ª The Royal Society of Chemistry 2011 Chem. Sci.
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‘‘bound’’ peaks previously in cases where the cryptophane
enantiomers are constrained near the protein target surface, and
the xenon by chance senses the environment identically inside
both biosensors.16 The short alkyl spacer for c[RGDyK] peptide
in 5 may similarly tether both cryptophane biosensor racemates
at the integrin receptor, effectively creating one xenon binding
site. Alternatively, a second peak corresponding to the other
diastereomer may reside under the ‘‘free’’ peak (!67 ppm).
The NMR binding assay described above was constrained by
a number of experimental factors. The concentrations were
selected to achieve a balance between the detection limit of our
current 129Xe NMR data collection method and the well docu-
mented aggregation behavior of this integrin protein. Integrin
protein aggregates at concentrations greater than 9 mM in solu-
tion without detergent, thus we limited experiments to 16–20 mM
integrin receptor with detergent.49,50 Another reason for the
‘‘bound’’ signal being weak is the broad line width compared to
some xenon biosensors bound to other protein targets (avidin,
0.15 ppm; carbonic anhydrase I and II, 0.19–0.27 ppm16). In
other cases, it has been observed that ‘‘bound’’ peaks for many
xenon biosensors are considerably broadened (10–30 Hz to 100–
150 Hz,14 and even 1–5 kHz20). Although peak broadening tends
to be an obstacle in identifying peaks in high-resolution NMR
spectra, this problem will be mitigated in a saturation transfer
scheme (Hyper-CEST).18 Given that we observe a 4 ppm chem-
ical shift change upon integrin binding, the ‘‘bound’’ and ‘‘free’’
peaks can be selectively saturated easily. This change in chemical
shift is comparable to our previous carbonic anhydrase biosensor
work (3.0–7.5 ppm)16 and a biosensor optimization study with
biotin–avidin (3–4 ppm).14 Considerably smaller 129Xe NMR
chemical shifts were observed in two related protein-binding
studies (biotin–avidin, !1 ppm;13 major histocompatibility
complex, !1 ppm51).
To make a competition assay (Fig. 4c), c[RGDyK] (100 mM)
was added to a fresh solution (1 mM Tris buffer, pH 7.2; 30%
glycerol and 0.1% Triton X-100) containing biosensor 5
(100 mM) and aIIbb3 integrin (20 mM). Here ‘‘free’’ cryptophane
gave the same 129Xe NMR chemical shift, and no ‘‘bound’’
cryptophane was detected, which indicated that the peptide
blocked 5 from binding to aIIbb3 integrin. The disappearance of
the smaller ‘‘bound’’ peak after addition of the competing
peptide further confirmed that the spectral change observed
upon addition of aIIbb3 is due to protein binding by the cryp-
tophane biosensor.
Conclusions
This work represents the first in-depth investigation of a xenon
NMR biosensor binding to proteins that are well recognized
cancer biomarkers and cell surface receptors. As such, we were
forced to confront challenges of poor solubility and aggregation
behavior involving both the integrin receptor and the biosensor
itself. We worked to engineer specific molecular interactions with
the avb3 integrin cancer biomarker and distinguish cancer cells
from healthy cells based on cell uptake properties. This work was
accomplished by conjugating the avb3 integrin receptor-targeting
peptide c[RGDyK] to a tripropargyl derivative of cryptophane-
A via a [3 + 2] cycloaddition reaction. This biosensor (3) was
found to bind avb3 and aIIbb3 integrin receptor proteins with the
expected nanomolar affinity (IC50 ¼ 20–30 nM), thus ensuring
the possibility of cell receptor targeting. The in vitro integrin
competitive binding assay confirmed that the cryptophane had
little effect on integrin receptor binding. Cryptophane was found
to be only moderately toxic to normal lung fibroblasts at relevant
biosensing concentrations although 50% viability was reached in
the cancer cell lines studied at concentrations of 75–100 mM.
Biosensor 4, labeled with Alexa Fluor 488, was useful for
fluorescence microscopy and flow cytometry experiments. These
studies confirmed that cryptophane was specifically targeted and
delivered into cells by an avb3 integrin receptor-mediated
pathway. Quantification of cellular delivery indicated that
internalization occurs at concentrations suitable for hyper-
polarized 129Xe NMR studies. Most importantly, internalization
was notably higher in AsPC-1 cancer cells compared to fibro-
blasts from the human lung, suggesting potential for targeted
delivery of cryptophanes in future in vivo studies.
Fig. 4 Hyperpolarized 129Xe NMR spectra of biosensor 5 alone, binding
aIIbb3 integrin, and blocked by c[RGDyK], all studies in Tris buffer
(1 mM, pH 7.2) (a) 5 gave 129Xe NMR chemical shift at 65.8 ppm. (b) 5
and aIIbb3 integrin in Tris buffer with 30% glycerol and 0.1% Triton
X-100. ‘‘Free’’ biosensor gave 129Xe NMR chemical shift at 67.1 ppm,
which was shifted 1.3 ppm downfield from ‘‘fre ’’ biosensor in (a) due to
addition of glycerol. ‘‘Bound’’ biosensor appeared at 71.2 ppm, repre-
senting a 4.1 ppm downfield shift. (c) c[RGDyK] added to solution of 5
and aIIbb3 integrin gave ‘‘free’’ biosensor at the same
129Xe NMR
chemical shift, but no ‘‘bound’’ biosensor was detected.
This journal is ª The Royal Society of Chemistry 2011 Chem. Sci.
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In an effort to perform similar binding experiments with the folate-conjugated 
xenon biosensor, 129Xe NMR spectroscopy methods with higher sensitivity need to be 
employed. In conventional hyperpolarized 129Xe NMR spectroscopy, most binding 
studies are performed at micromolar concentrations of cryptophane biosensor, however 
targets such as the folate binding protein (FBP) and integrin receptors tend to aggregate at 
such concentrations, which limits the utility of this approach. In recent years, an ultra-
sensitive NMR technique called Hyper-CEST (hyperpolarized 129Xe chemical exchange 
saturation transfer) has been successfully utilized to detect 0.7 pM virus capsid with 125 
cryptophanes attached (87 pM cryptophane equivalent).12  Hyper-CEST is a technique 
that can amplify cryptophane cage-related magnetization by using a specific RF pulse 
that selectively saturates the biosensor-encapsulated Xe magnetization.13 Following 
chemical exchange with the free Xe in solution, a high population of depolarized nuclei is 
accumulated.13 After several cycles of continuous depolarization of the cage-related 
magnetization, the signal can be measured indirectly by calculating the difference 
between initial and final bulk (Xe in solution) magnetization.13 Yubin Bai in our 
laboratory has been working on the detection of water-soluble cryptophanes at low 
concentrations using Hyper-CEST. Recently, we were able to detect TAAC at very low 
concentrations (1.4 pM), which sets the new lowest detectable concentration for 
cryptophanes using this technique. Therefore, the next step will involve optimizing the 
Hyper-CEST conditions and using it to detect NMR resonances produced as a result of 
the folate-conjugated cryptophane binding to the monomeric FBP at nanomolar or 
picomolar concentrations.  
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Another advancement in the use of hyperpolarized 129Xe gas towards in vivo 
applications includes the ability to perform cellular 129Xe NMR spectroscopy on a variety 
of prokaryotic and eukaryotic cells.14 The cell density in these experiments ranged from 
42 to 162 million cells per mL, with typically 0.5 mL sample volumes.14 The NMR 
spectra of intact cells from various cell lines were shown to consist of two distinct peaks: 
peak 1 at 199.5 ppm was assigned to intracellular components whereas peak 2 at 195.5 
ppm was assigned to extracellular components (Figure 5.2). Such distinct peak separation 
may make it possible to differentiate tumor and healthy cells by hyperpolarized 129Xe 
NMR spectroscopy due to differences in membrane flexibility or internal pH.14 Recent 
studies have also focused on imaging human lungs and quantifying blood flow to human 
brains using hyperpolarized 129Xe gas.15,16 Using conventional 1H MRI, lungs are difficult 
to image due to low proton concentration in the airways. Such limitations make 129Xe gas 
a very attractive imaging agent for lungs since it is possible to continuously replenish 
hyperpolarized 129Xe gas via inhalation and breath holds. 
 
 
 
 
 
 
 
 
 184 
 
Figure 5.2. Hyperpolarized 129Xe NMR spectra of (a) 42 million cells/mL; (b) 83 million 
cells/mL; (c) 167 million cells/mL with K562 cells in phosphate-buffered saline at 277 K. 
Each sample contained approximately 5 mM of dissolved xenon. Figure was adapted 
from Boutina et al.14 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS
Sample preparation
Human erythroleukemic K562 cells were purchased from the
American Type Culture Collection (ATCC) and grown in Iscove’s
modified Dulbecco’s medium (Sigma-Aldrich, St Louis, MO, USA).
A549 lung epithelial cells (CCL-185) and NRK-52E renal proximal
cells (CRL-1571) were also purchased from ATCC, and grown in
Dulbecco’s modified essential medium (Sigma-Aldrich). Both
media were supplemented with 10% heat-inactivated fetal
bovine serum, 1% L-glutamine, 100 U/mL penicillin and 100 g/mL
streptomycin. The cells weremaintained in exponential growth in
a 5% CO2 incubator at 37 8C. In one condition, A549 cells were
exposed for 24 h to 500mM of cobalt, prepared from a 10mM stock
solution, diluted in Dulbecco’s modified essential medium. Prior
to the NMR experiment, the cells were washed three times in
phosphate-buffered saline (pH 7.4) and viable cells were counted
using trypan blue exclusion. The chosen amount of cells was
resuspended to a final volume of 500mL.
Escherichia coli TOP10 (Invitrogen, Carlsbad, New Mexico, USA)
bacteria were grown at 37 8C, under agitation, in Luria–Bertani
medium. Synechocystis sp. strain PCC 6803 was grown auto-
trophically in liquid minimal mineral medium BG-11 (Sig-
ma-Aldrich) at 29 8C under constant white light (2000–3000 lx)
and agitation. At the end of the exponential growth phase, they
were collected, rinsed three times with water and resuspended in
500mL of phosphate-buffered saline (pH 7.4).
The yeast strain used was Saccharomyces cerevisiae W303.1b.
Yeast was grown in a rich medium containing 2% (w/v) BactoTM
peptone, 2% (w/v) yeast extract, 1% (w/v) glucose and 2.7% (v/v)
ethanol, at 28 8C, in a Techfors-S bioreactor (Infors-HT, Bottmin-
gen, Switzerland) with stirring at 300 rpm and dissolved O2
maintained above 20%.
For each cell type, the cell suspensions were introduced into
NMR tubes equipped with J. Young valves. These suspensions
were degassed by helium bubbling for 5min; the excess gas was
removed by Joule–Gay Lussac expansion (static pumping). This
procedure ensured that the integrity of the cells remained during
the course of the NMR experiment, as checked by microscopy
afterwards.
Optical pumping
Hyperpolarized xenon was prepared via the spin-exchange
method (11) using a home-built batch apparatus (12). Frozen
xenon was transported to the NMR room using a ‘U’-shaped
tube that was placed inside a 3-kG solenoid immersed in liquid
nitrogen. It was then sublimated and transferred into the NMR
tube containing the sample previously degassed via a vacuum
line. To achieve such a transfer, xenon was condensed in the
upper part of the NMR tube with a specially designed Dewar
that surrounded the tube, enabling the formation of a cold
point above the solution. This operation occurred in the fringe
field of the NMR magnet in order to preserve polarization.
129Xe NMR experiments
The 129Xe NMR spectra were recorded on a Bruker Avance II 500
spectrometer (Bruker, Ettlingen, Germany) equipped with a
5-mm-diameter 129Xe/1H probehead (129Xe resonance frequency,
138.4MHz). After the xenon transfer and before each 129Xe NMR
experiment, the NMR tube was shaken in order to refresh the
solution in hyperpolarized xenon. A delay on the order of 10 s then
ensured that the gas bubbles disappeared from the detection region.
It was checked that such a procedure did not accelerate cell death
significantly and did not lead to a variation in the xenon chemical
shifts according to gas pressure. Furthermore, the recorded spectra
contained no gas peak. Therefore, no change in chemical shift could
arise from the influence of xenon in bubbles. In order to calibrate the
signals, the NMR tube was displaced vertically in a second
experiment, so that the detection region now included the gas,
thereby providing the signal at 0ppm.
The exchange experiment was performed using an I2SNOB
inversion pulse of 2ms, followed by a variable delay and a hard
pulse. As our polarization level could vary between experiments,
normalization of the peak areas was performed using a previous
simple xenon acquisition with a small flip angle.
All the displayed spectra correspond to the real part of
the signal obtained in a single scan without averaging, after
apodization by an exponential function (20-Hz Lorentzian
broadening) of the free induction decay, Fourier transformation
and phasing. The observed difference in signal-to-noise ratios
can be explained by the different levels of spin hyperpolarization.
RESULTS AND DISCUSSION
129Xe NMR spectra were recorded on eukaryotic and prokaryotic
cells using dissolved hyperpolarized gas. In such 129Xe spectra of
living biological cells, two signals around 200 ppm (with respect
to the signal of the gas phase at 0 ppm) are observed. As an
example, Fig. 1 displays the spectra of suspensions of K562 cells in
their culture medium at different concentrations. It is worth
noting that the intensity of peak 1 at 199.5 ppm follows the
number of cells present in the detection region. Fitting by
Figure 1. Low-field region of laser-polarized 129Xe spectra obtained in
one scan of three K562 cell populations suspended in phosphate-buffered
saline: (a) 42 million cells/mL; (b) 83 million cells/mL; (c) 167 million cells/
mL. Experiments were performed at 11.7 T and 277 K. Each sample
contained approximately 1 bar of laser-polarized gas on top of the liquid,
which roughly corresponds to 5mM of dissolved xenon. The intensities of
the largest peak were arbitrarily scaled at the same level. Inset: ratio of the
two observed peak areas R as a function of the intra- to extracellular
v lume fraction D. The best-fit straight line is superimposed.
wileyonlinelibrary.com/journal/nbm Copyright ! 2011 John Wiley & Sons, Ltd. NMR Biomed. (2011)
C. BOUTIN ET AL.
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The ability to perform cellular NMR imaging using hyperpolarized 129Xe gas has 
also motivated the development of cryptophane-based pH biosensors in the Dmochowski 
group. Intracellular pH is critical for various functions in cells such as proliferation and 
apoptosis,17-21 endocytosis,18 and multidrug resistance.22 However, abnormal changes in 
pH due to modifications in cellular functions, growth and division have been associated 
with cancer23 and Alzheimer’s.24 Therefore, the development of 129Xe biosensors that can 
clearly distinguish changes in both intra- and extracelluar pH would assist in the sensitive 
detection of various diseases.  
 
To develop such a biosensor, a recent design from our laboratory included 
conjugating a GALA peptide to tripropargyl cryptophane by utilizing the Huisgen [3+2] 
cycloaddition reaction. The water-soluble GALA peptide consists of 30 amino acids  
(WEAALAEALAEALAEHLAEALAEALEALAA) with a repeat sequence of glutamic 
acid-alanine-leucine-alanine (Figure 5.3a).25 The apolar leucines confer relatively high 
hydrophobicity, the polar glutamic acids add a pH-dependent component to the 
hydrophobicity and net charge while the alanine residues act as spacers between the polar 
and apolar faces of the helix.25 It also contains a histidine and tryptophan residue for 
NMR and fluorescence purposes. GALA is known to interact with the lipid bilayer 
preferentially at acidic pH as it undergoes a coil to α-helical transition from pH 5.0 to 
7.5.25 At pH 5.0, some of the glutamic acids (with carboxylate side chains) are 
protonated, which promotes the formation of an α-helical coil. At pH 7.5, electrostatic 
charge repulsions between the deprotonated carboxylates on the glutamic acid residues 
destabilize the helix. Circular dichroism (CD) measurements performed on GALA 
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indicated that the molar ellipticity at 222 nm changed dramatically from -11,500 deg cm2 
dmol-1 at pH 5.1 to -4,000 deg cm2 dmol-1 at pH 7.6, which is consistent with a decrease 
in helical content as the pH was increased (Figure 5.3).25 This peptide has been used in 
previous studies for pH-triggered lysis of liposomes, because at pH 5.0 the liposomes 
leak as GALA becomes incorporated into the vesicle bilayer and aggregates to form a 
transbilayer pore.25,26  
  
 
Due to xenon’s polarizability and sensitivity to molecular environment, we expect 
that a GALA-conjugated cryptophane will reflect a distinct 129Xe NMR chemical shift 
due to the conformational changes in the peptide from pH 5.0 to 7.5. Figure 5.4 shows the 
potential synthetic scheme for such a biosensor. If the GALA-conjugated cryptophane is 
not highly water-soluble, 2-azido propionic acid groups could also be “clicked” on to 
improve solubility, as was done with the integrin and carbonic anhydrase targeting 
biosensors.5,27 The synthesis of this biosensor is currently underway. 
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Figure 5.3. a) Circular dichroism spectra of GALA in 5 mM TES buffer, 100 mM KCl at 
varying pH, b) Structural representations of the GALA peptide with side view along the 
helical axis and end view of the C-terminus. Oxygen, carbon, nitrogen, hydrogen and 
sulfur atoms are represented by red, light blue, dark blue, white and yellow color, 
respectively, c) Helical grid representation of GALA demonstrating the stacking of the 
glutamic acid residues. Figure was adapted from Subbarao and Li, et al.25,26  
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Figure 5.4. Synthetic scheme of a GALA-conjugated cryptophane pH sensor. 
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As mentioned in Chapter 1, our lab has synthesized several carbonic anhydrase 
(CA)-targeting biosensors where the recognition moiety consisted of a 
benzenesulfonamide group attached to the cryptophane by a variable-length linker. These 
biosensors exhibited the largest changes in chemical shifts upon binding to CA (3.0-7.5 
ppm) and were able to differentiate between CA I and II isozymes, showing either 1 or 2 
“bound” peaks.27 We hypothesized that this was due to the presence of racemic mixtures 
(+/-) of enantiomers for the biosensor, which formed diastereomers once bound to the 
chiral protein. In order to perform multiplexing with hyperpolarized 129Xe MR imaging 
and maintain high signal-to-noise, it is pertinent to reduce the number of NMR 
resonances due to racemic mixtures. To achieve this goal, enantiomerically pure 
cryptophanes are currently being synthesized by Dr. Olena Taratula in our lab. The 
synthetic scheme for making enatiomerically pure cryptophanes involves the deprotection 
of tri-substituted cryptophane using a Pd catalyst to afford tri-hydroxyl cryptophane 
(Figure 5.5a). Tri-hydroxyl cryptophane can then be reacted with 3 equiv. (S)-Mosher’s 
acid in the presence of DMAP/Et3N. The two resulting cryptophane-A diastereomers 2a 
and 2b functionalized with the three chiral auxillaries are successfully separated by 
column chromatography. In previous studies, in an effort to synthesize enantiomerically 
pure cryptophanes, diastereomers of mono(-)camphanic ester cryptophanes had also been 
synthetized which required HPLC purification for effective separation.28 Once the 
diastereomers are separated using column chromatography, they can be deprotected via 
basic hydrolysis affording enantiopure tri-hydroxyl cryptophanes (-) 3a and (+) 3b. 
Finally, reaction with 3 equiv. propargyl bromide would give the enantiomerically pure 
cryptophane (-) 4a and (+) 4b. Targeting moieties such as the benzesulfonamide group or 
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folate recognition moiety can then be attached by [3+2] cycloaddition to synthesize a 
variety of enantiomerically pure 129Xe cryptophane biosensors.  
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Figure 5.5. a) Synthesis of enantiopure tripropargyl cryptophanes, b) Synthesis of future 
enantiopure CA biosensors, c) Circular dichroism spectra confirming the separation of 
(+) 2a and (-) 2a diastereomers by column chromatography. Figure adapted from Dr. 
Olena Taratula (Personal communication). 
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Lastly, in Chapter 4 we outlined a new application for a tribenzylamine 
hemicryptophane where the cage could be utilized to develop molecular devices. A 
tribenzylamine moiety was connected to a cyclotriveratrylene (CTV) unit to form a new 
hemicryptophane, which resembled a macroscopic gyroscope. Similar to a gyroscope, it 
had a stator (amine and the CTV unit) with multiple rotators (p-phenylene groups). 1H 
variable temperature NMR spectroscopy and molecular dynamics simulations were in 
agreement that the rotation energy barrier of the rotators was approximately 10 kcal/mol. 
Currently, computational studies are underway in collaboration with the Saven group to 
determine how structural changes in the cage (e.g., removal of the methoxy groups, 
incorporation of different moieties with dipole moments or bulkier substituents) may alter 
the rotational barrier of the p-phenylene groups. One can imagine that by engineering 
hemicryptophanes with rotators that undergo unidirectional motion, it should be possible 
to direct their movement in solution or on surfaces. 
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APPENDIX A: X-RAY STUCTURE DETERMINATION OF 
TRIBENZYLAMINE HEMICRYPTOPHANE 
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Tribenzylamine hemicryptophane, C48H45NO6, crystallizes in the monoclinic 
space group P21/c (systematic absences 0k0: k = odd and h0l: l = odd) with a = 
17.098(2)Å, b = 11.4592(9)Å, c = 21.096(2)Å, β = 113.539(2)°, V = 3789.3(6)Å3, Z = 4 
and dcalc = 1.283 g/cm
3.  X-ray intensity data were collected on a Rigaku Mercury CCD 
area detector employing graphite-monochromated Mo-Kα radiation (λ = 0.71073 Å) at a 
temperature of 143 K. Preliminary indexing was performed from a series of twelve 0.5° 
rotation images with exposures of 30 seconds. A total of 336 rotation images were 
collected with a crystal to detector distance of 35 mm, a 2θ swing angle of -12°, rotation 
widths of 0.5° and exposures of 10 seconds: scan no. 1 was a φ-scan from 170° to 338° at 
ω = 0° and χ = 0°.  Rotation images were processed using CrystalClear,1 producing a 
listing of unaveraged F2 and σ(F2) values which were then passed to the 
CrystalStructure2 program package for further processing and structure solution on a Dell 
Pentium III computer. A total of 15571 reflections were measured over the ranges 5.2 
≤2θ ≤50.02 °,  -16 ≤	 h ≤	 20,  -13 ≤	 k ≤	 12,  -23 ≤	 l ≤	 25 yielding 6601 unique 
reflections (Rint = 0.0261). The intensity data were corrected for Lorentz and polarization 
effects and for absorption using REQAB3 (minimum and maximum transmission 0.853, 
1.000). 
 
 The structure was solved by direct methods (SIR97).4 Refinement was by full-
matrix least squares based on F2 using SHELXL-97.  5 All reflections were used during 
refinement (F2 ’s that were experimentally negative were replaced by F2 = 0). The 
weighting scheme used was w = 1/[σ2(Fo
2 )+ 0.0547P2 + 0.9350P] where P = (Fo
2  + 2F c
2 
)/3. Non-hydrogen atoms were refined anisotropically and hydrogen atoms were refined 
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using a "riding" model.  Refinement converged to R1 = 0.0479 and wR2 = 0.1107 for 5502 
reflections for which F > 4σ(F) and R1 = 0.0599, wR2 = 0.1204 and GOF = 1.078 for all 
6601 unique, non-zero reflections and 500 variables.  6 The maximum Δ/σ in the final 
cycle of least squares was 0.001 and the two most prominent peaks in the final difference 
Fourier were +0.173 and -0.253 e/Å3. 
 
 Table 1 lists cell information, data collection parameters, and refinement data.  
Final positional and equivalent isotropic thermal parameters are given in Table 2.  
Anisotropic thermal parameters are in Table 3.  Tables 4 and 5 list bond distances and 
bond angles.  Figure 1 is an ORTEP7 representation of the molecule with 30% probability 
thermal ellipsoids displayed. 
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Figure 1. ORTEP drawing of the title compound with 30% probability thermal ellipsoids. 
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Table 1.  Summary of Structure Determination of Tribenzylamine Hemicryptophane 
Formula: C48H45NO6 
Formula weight: 731.85 
Crystal class: monoclinic 
Space group: P21/c (#14) 
Z 4 
Cell constants:  
 a 17.098(2)Å 
 b  11.4592(9)Å 
 c 21.096(2)Å 
 β 113.539(2)° 
 V  3789.3(6)Å3 
µ 0.84 cm- 1 
crystal size, mm 0.40 x 0.30 x 0.15 
Dcalc 1.283 g/cm3 
F(000) 1552 
Radiation: Mo-Kα (λ = 0.71073Å) 
2θ range 5.2 – 50.02° 
hkl collected: -16 ≤	 h ≤	 20; -13 ≤	 k ≤	 12;  
-23≤	 l ≤	 25 
No. reflections measured: 15571 
No. unique reflections: 6601 (Rint = 0.0261) 
No. observed reflections 5502 (F>4σ) 
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No. reflections used in refinement 6601 
No. parameters 500 
R indices (F>4σ) R1 = 0.0479 
 wR2 = 0.1107 
R indices (all data) R1 = 0.0599 
 wR2 = 0.1204 
GOF: 1.078 
Final Difference Peaks, e/Å3 +0.173, -0.253 
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Table 2.  Refined Positional Parameters for Tribenzylamine Hemicryptophane 
 
       Atom                 x                             y                                z                             Ueq, Å2 
C1 0.68997(11) 0.3795(2) 0.29839(9) 0.0268(4) 
H1a 0.6451 0.3270 0.2672 0.036 
H1b 0.7209 0.3367 0.3421 0.036 
C2 0.75236(11) 0.40673(14) 0.26512(9) 0.0246(4) 
C3 0.84043(11) 0.41596(14) 0.30238(9) 0.0244(4) 
C4 0.89146(11) 0.4396(2) 0.26611(9) 0.0264(4) 
H4 0.9515 0.4432 0.2911 0.035 
C5 0.85851(11) 0.4579(2) 0.19571(9) 0.0261(4) 
C6 0.77077(11) 0.4453(2) 0.15789(9) 0.0281(4) 
C7 0.71970(11) 0.4191(2) 0.19298(9) 0.0273(4) 
H7 0.6602 0.4092 0.1672 0.036 
C8 0.65700(13) 0.4318(2) 0.04641(11) 0.0506(6) 
H8a 0.6450 0.3517 0.0562 0.076 
H8b 0.6468 0.4387 -0.0026 0.076 
H8c 0.6196 0.4859 0.0571 0.076 
C9 0.97285(11) 0.5726(2) 0.19077(10) 0.0299(4) 
H9a 1.0114 0.5752 0.1661 0.040 
H9b 1.0073 0.5514 0.2395 0.040 
C10 0.93397(10) 0.6912(2) 0.18818(9) 0.0268(4) 
C11 0.92045(10) 0.7637(2) 0.13235(9) 0.0276(4) 
H11 0.9395 0.7403 0.0977 0.037 
C12 0.87924(11) 0.8709(2) 0.12626(9) 0.0276(4) 
 203 
H12 0.8709 0.9197 0.0877 0.037 
C13 0.85038(11) 0.9070(2) 0.17561(9) 0.0270(4) 
C14 0.86559(12) 0.8350(2) 0.23278(10) 0.0329(4) 
H14 0.8472 0.8591 0.2677 0.044 
C15 0.90709(12) 0.7294(2) 0.23933(9) 0.0320(4) 
H15 0.9175 0.6821 0.2789 0.042 
C16 0.80156(11) 1.0198(2) 0.16882(10) 0.0306(4) 
H16a 0.8320 1.0701 0.2094 0.041 
H16b 0.7981 1.0620 0.1268 0.041 
C17 0.88499(11) 0.4075(2) 0.38059(9) 0.0246(4) 
H17a 0.9415 0.3704 0.3932 0.033 
H17b 0.8509 0.3577 0.3984 0.033 
C19 0.83844(10) 0.5756(2) 0.43743(8) 0.0236(4) 
C20 0.85107(10) 0.6909(2) 0.46236(8) 0.0250(4) 
H20 0.8110 0.7241 0.4780 0.033 
C21 0.91926(11) 0.7572(2) 0.46494(9) 0.0246(4) 
C22 0.97914(10) 0.7078(2) 0.44247(9) 0.0255(4) 
C23 0.96706(11) 0.5946(2) 0.41771(9) 0.0249(4) 
H23 1.0077 0.5611 0.4028 0.033 
C18 0.89641(10) 0.5275(2) 0.41390(8) 0.0231(4) 
C24 1.10639(11) 0.7335(2) 0.42323(10) 0.0339(5) 
H24a 1.1326 0.6623 0.4485 0.051 
H24b 1.1508 0.7921 0.4298 0.051 
H24c 1.0770 0.7157 0.3739 0.051 
C25 0.86890(11) 0.9424(2) 0.49063(9) 0.0284(4) 
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H25a 0.8923 1.0113 0.5205 0.038 
H25b 0.8321 0.8992 0.5088 0.038 
     
     
C26 0.81656(11) 0.9819(2) 0.41791(9) 0.0271(4) 
C27 0.84351(11) 1.0774(2) 0.39113(9) 0.0296(4) 
H27 0.8925 1.1200 0.4199 0.039 
C28 0.79946(12) 1.1112(2) 0.32269(10) 0.0303(4) 
H28 0.8184 1.1773 0.3056 0.040 
C29 0.72828(11) 1.0500(2) 0.27887(9) 0.0278(4) 
C30 0.70048(11) 0.9553(2) 0.30603(10) 0.0299(4) 
H30 0.6515 0.9127 0.2772 0.040 
C31 0.74325(11) 0.9228(2) 0.37437(10) 0.0304(4) 
H31 0.7225 0.8592 0.3921 0.040 
C32 0.68496(12) 1.0772(2) 0.20272(9) 0.0305(4) 
H32a 0.6224 1.0698 0.1872 0.041 
H32b 0.6981 1.1583 0.1940 0.041 
C33 0.76095(11) 0.5109(2) 0.43731(9) 0.0260(4) 
H33a 0.7705 0.4260 0.4353 0.035 
H33b 0.7550 0.5271 0.4813 0.035 
C34 0.67860(10) 0.5436(2) 0.37776(9) 0.0249(4) 
C35 0.64710(11) 0.4857(2) 0.31415(9) 0.0249(4) 
C36 0.57016(11) 0.5239(2) 0.26292(9) 0.0264(4) 
H36 0.5473 0.4828 0.2203 0.035 
C37 0.52585(10) 0.6194(2) 0.27182(9) 0.0272(4) 
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C38 0.55679(11) 0.6754(2) 0.33629(9) 0.0265(4) 
C39 0.63139(11) 0.6363(2) 0.38791(9) 0.0264(4) 
H39 0.6514 0.6734 0.4318 0.035 
C40 0.53370(13) 0.8133(2) 0.41162(10) 0.0403(5) 
H40a 0.5307 0.7524 0.4432 0.061 
H40b 0.4957 0.8778 0.4109 0.061 
H40c 0.5924 0.8420 0.4274 0.061 
C41 0.43175(11) 0.6401(2) 0.15108(9) 0.0302(4) 
H41a 0.3705 0.6548 0.1232 0.040 
H41b 0.4438 0.5575 0.1446 0.040 
C42 0.48468(11) 0.7182(2) 0.12638(9) 0.0281(4) 
C43 0.56745(11) 0.6877(2) 0.13472(10) 0.0337(4) 
H43 0.5880 0.6113 0.1497 0.045 
C44 0.61975(11) 0.7673(2) 0.12146(10) 0.0337(4) 
H44 0.6761 0.7452 0.1282 0.045 
C45 0.59082(11) 0.8795(2) 0.09831(9) 0.0295(4) 
C46 0.50707(12) 0.9073(2) 0.08574(9) 0.0318(4) 
H46 0.4851 0.9817 0.0673 0.042 
C47 0.45492(11) 0.8278(2) 0.09974(9) 0.0312(4) 
H47 0.3978 0.8488 0.0909 0.042 
C48 0.65400(12) 0.9685(2) 0.09431(9) 0.0329(4) 
H48a 0.6841 0.9371 0.0665 0.044 
H48b 0.6236 1.0404 0.0716 0.044 
N1 0.71561(9) 0.99538(13) 0.16430(7) 0.0281(3) 
O1 0.74317(8) 0.45924(12) 0.08764(6) 0.0387(3) 
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O2 0.90822(8) 0.48420(11) 0.15958(6) 0.0317(3) 
O3 1.04669(7) 0.77780(11) 0.44864(7) 0.0318(3) 
O4 0.93840(7) 0.86765(10) 0.49263(6) 0.0281(3) 
O5 0.50798(8) 0.76623(11) 0.34394(7) 0.0338(3) 
O6 0.45025(7) 0.66099(11) 0.22319(6) 0.0310(3) 
Ueq=1/3[U11(aa*)2+U22(bb*)2+U33(cc*)2+2U12aa*bb*cosγ+2U13aa*cc*cosβ+2U23bb*cc*
cosα] 
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Table 3.   Refined Thermal Parameters (U's) for Tribenzylamine Hemicryptophane 
 
       Atom           U11             U22           U33                  U23                U13            U12 
C1 0.0279(9) 0.0225(9) 0.0288(10) -0.0014(8) 0.0100(8) -0.0033(8) 
C2 0.0275(9) 0.0184(9) 0.0265(9) -0.0019(7) 0.0093(8) 0.0002(7) 
C3 0.0282(9) 0.0172(8) 0.0261(9) -0.0015(7) 0.0091(8) 0.0015(7) 
C4 0.0249(9) 0.0241(9) 0.0289(10) -0.0028(8) 0.0094(8) 0.0007(8) 
C5 0.0291(9) 0.0229(9) 0.0291(10) -0.0021(8) 0.0145(8) -0.0004(8) 
C6 0.0316(10) 0.0286(10) 0.0219(9) -0.0001(8) 0.0085(8) 0.0035(8) 
C7 0.0238(9) 0.0255(9) 0.0281(10) -0.0039(8) 0.0054(8) 0.0000(8) 
C8 0.0399(12) 0.078(2) 0.0250(11) -0.0015(11) 0.0035(9) -0.0016(12) 
C9 0.0246(9) 0.0341(10) 0.0326(11) 0.0002(8) 0.0131(8) -0.0025(8) 
C10 0.0224(9) 0.0303(10) 0.0259(10) -0.0012(8) 0.0079(7) -0.0033(8) 
C11 0.0256(9) 0.0324(10) 0.0254(10) -0.0042(8) 0.0109(8) -0.0063(8) 
C12 0.0284(9) 0.0273(10) 0.0248(9) -0.0006(8) 0.0084(8) -0.0046(8) 
C13 0.0228(9) 0.0278(10) 0.0286(10) -0.0013(8) 0.0085(8) -0.0040(8) 
C14 0.0383(10) 0.0351(11) 0.0293(10) -0.0006(8) 0.0177(9) 0.0025(9) 
C15 0.0367(10) 0.0338(11) 0.0256(10) 0.0043(8) 0.0127(8) 0.0029(9) 
C16 0.0313(10) 0.0281(10) 0.0325(10) 0.0004(8) 0.0129(8) -0.0036(8) 
C17 0.0234(9) 0.0223(9) 0.0265(10) 0.0009(7) 0.0082(7) 0.0018(7) 
C19 0.0238(9) 0.0259(9) 0.0182(9) 0.0024(7) 0.0053(7) 0.0015(7) 
C20 0.0243(9) 0.0284(9) 0.0209(9) -0.0012(7) 0.0076(7) 0.0029(8) 
C21 0.0281(9) 0.0221(9) 0.0196(9) -0.0014(7) 0.0053(7) 0.0013(8) 
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C22 0.0232(9) 0.0272(9) 0.0236(9) 0.0012(8) 0.0067(7) -0.0006(8) 
C23 0.0257(9) 0.0269(10) 0.0222(9) -0.0004(7) 0.0095(7) 0.0042(8) 
C18 0.0244(9) 0.0233(9) 0.0177(9) 0.0019(7) 0.0042(7) 0.0023(7) 
C24 0.0291(10) 0.0342(11) 0.0416(12) 0.0006(9) 0.0174(9) 0.0017(9) 
C25 0.0324(10) 0.0243(9) 0.0283(10) -0.0015(8) 0.0118(8) 0.0049(8) 
C26 0.0296(9) 0.0227(9) 0.0285(10) -0.0024(8) 0.0112(8) 0.0042(8) 
C27 0.0307(10) 0.0228(9) 0.0303(10) -0.0025(8) 0.0069(8) 0.0002(8) 
C28 0.0353(10) 0.0209(9) 0.0337(11) 0.0006(8) 0.0128(9) 0.0011(8) 
C29 0.0280(9) 0.0259(10) 0.0287(10) 0.0002(8) 0.0107(8) 0.0064(8) 
C30 0.0246(9) 0.0314(10) 0.0312(10) -0.0012(8) 0.0085(8) 0.0004(8) 
C31 0.0289(10) 0.0291(10) 0.0343(11) 0.0026(8) 0.0137(8) 0.0005(8) 
C32 0.0317(10) 0.0273(10) 0.0299(10) 0.0008(8) 0.0098(8) 0.0059(8) 
C33 0.0280(9) 0.0271(9) 0.0232(9) 0.0013(7) 0.0107(8) 0.0005(8) 
C34 0.0237(9) 0.0254(9) 0.0266(10) 0.0019(7) 0.0110(8) -0.0028(8) 
C35 0.0246(9) 0.0235(9) 0.0281(10) 0.0014(8) 0.0120(8) -0.0037(8) 
C36 0.0244(9) 0.0279(9) 0.0256(10) -0.0043(8) 0.0087(8) -0.0046(8) 
C37 0.0218(9) 0.0300(10) 0.0288(10) 0.0008(8) 0.0092(8) -0.0030(8) 
C38 0.0252(9) 0.0264(10) 0.0299(10) -0.0024(8) 0.0132(8) -0.0012(8) 
C39 0.0262(9) 0.0281(10) 0.0252(10) -0.0014(8) 0.0105(8) -0.0035(8) 
C40 0.0394(11) 0.0439(12) 0.0354(11) -0.0086(9) 0.0124(9) 0.0104(10) 
C41 0.0236(9) 0.0389(11) 0.0246(10) -0.0021(8) 0.0059(8) 0.0000(8) 
C42 0.0243(9) 0.0321(10) 0.0244(10) -0.0042(8) 0.0061(8) -0.0003(8) 
C43 0.0310(10) 0.0295(10) 0.0408(11) 0.0030(9) 0.0145(9) 0.0043(8) 
C44 0.0255(9) 0.0360(11) 0.0410(12) 0.0029(9) 0.0147(9) 0.0047(9) 
C45 0.0308(10) 0.0331(10) 0.0230(9) -0.0032(8) 0.0092(8) -0.0008(8) 
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C46 0.0347(10) 0.0300(10) 0.0273(10) -0.0002(8) 0.0088(8) 0.0045(9) 
C47 0.0259(9) 0.0373(11) 0.0282(10) -0.0028(8) 0.0083(8) 0.0028(8) 
C48 0.0347(10) 0.0374(11) 0.0253(10) -0.0001(8) 0.0108(8) -0.0035(9) 
N1 0.0274(8) 0.0297(8) 0.0265(8) -0.0033(7) 0.0102(7) -0.0011(7) 
       
       
O1 0.0343(7) 0.0554(9) 0.0230(7) 0.0001(6) 0.0079(6) 0.0007(7) 
O2 0.0349(7) 0.0328(7) 0.0314(7) -0.0047(6) 0.0173(6) -0.0031(6) 
O3 0.0306(7) 0.0292(7) 0.0399(8) -0.0068(6) 0.0186(6) -0.0052(6) 
O4 0.0282(6) 0.0234(6) 0.0302(7) -0.0048(5) 0.0090(5) 0.0005(5) 
O5 0.0312(7) 0.0368(8) 0.0320(7) -0.0039(6) 0.0113(6) 0.0072(6) 
O6 0.0230(6) 0.0422(8) 0.0257(7) 0.0001(6) 0.0075(5) 0.0039(6) 
The form of the anisotropic displacement parameter is: 
exp[-2π2(a*2U11h2+b*2U22k2+c*2U33l2+ 2b*c*U23kl+2a*c*U13hl+2a*b*U12hk)]. 
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Table 4.   Bond Distances in Tribenzylamine Hemicryptophane, Å 
 
C1-C35 1.524(2) C1-C2 1.525(2) C2-C3 1.397(2) 
C2-C7 1.403(2) C3-C4 1.398(2) C3-C17 1.519(2) 
C4-C5 1.378(2) C5-O2 1.383(2) C5-C6 1.397(2) 
C6-O1 1.373(2) C6-C7 1.384(3) C8-O1 1.415(2) 
C9-O2 1.449(2) C9-C10 1.505(3) C10-C11 1.383(2) 
C10-C15 1.401(2) C11-C12 1.396(3) C12-C13 1.381(3) 
C13-C14 1.397(3) C13-C16 1.514(3) C14-C15 1.382(3) 
C16-N1 1.461(2) C17-C18 1.521(2) C19-C18 1.388(2) 
C19-C20 1.406(2) C19-C33 1.517(2) C20-C21 1.374(2) 
C21-O4 1.378(2) C21-C22 1.408(2) C22-O3 1.369(2) 
C22-C23 1.383(2) C23-C18 1.407(2) C24-O3 1.423(2) 
C25-O4 1.452(2) C25-C26 1.504(2) C26-C27 1.392(3) 
C26-C31 1.398(3) C27-C28 1.390(3) C28-C29 1.389(3) 
C29-C30 1.396(3) C29-C32 1.509(2) C30-C31 1.382(3) 
C32-N1 1.466(2) C33-C34 1.512(2) C34-C35 1.398(2) 
C34-C39 1.401(2) C35-C36 1.398(2) C36-C37 1.386(2) 
C37-O6 1.375(2) C37-C38 1.402(2) C38-C39 1.380(2) 
C38-O5 1.383(2) C40-O5 1.422(2) C41-O6 1.445(2) 
C41-C42 1.506(3) C42-C47 1.387(3) C42-C43 1.399(2) 
C43-C44 1.381(3) C44-C45 1.394(3) C45-C46 1.385(3) 
C45-C48 1.512(3) C46-C47 1.387(3) C48-N1 1.464(2) 
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Table 5.   Bond Angles in Tribenzylamine Hemicryptophane, ° 
 
C35-C1-C2 115.01(14) C3-C2-C7 118.4(2) C3-C2-C1 123.5(2) 
C7-C2-C1 118.1(2) C2-C3-C4 118.4(2) C2-C3-C17 124.5(2) 
C4-C3-C17 117.1(2) C5-C4-C3 122.9(2) C4-C5-O2 123.4(2) 
C4-C5-C6 118.9(2) O2-C5-C6 117.6(2) O1-C6-C7 125.7(2) 
O1-C6-C5 115.6(2) C7-C6-C5 118.7(2) C6-C7-C2 122.6(2) 
O2-C9-C10 111.67(14) C11-C10-C15 118.3(2) C11-C10-C9 119.7(2) 
C15-C10-C9 122.0(2) C10-C11-C12 120.9(2) C13-C12-C11 120.8(2) 
C12-C13-C14 118.4(2) C12-C13-C16 122.2(2) C14-C13-C16 119.4(2) 
C15-C14-C13 121.0(2) C14-C15-C10 120.6(2) N1-C16-C13 110.18(14) 
C3-C17-C18 111.11(13) C18-C19-C20 118.8(2) C18-C19-C33 123.6(2) 
C20-C19-C33 117.6(2) C21-C20-C19 122.3(2) C20-C21-O4 125.4(2) 
C20-C21-C22 118.9(2) O4-C21-C22 115.5(2) O3-C22-C23 125.4(2) 
O3-C22-C21 115.6(2) C23-C22-C21 119.1(2) C22-C23-C18 122.0(2) 
C19-C18-C23 118.8(2) C19-C18-C17 123.1(2) C23-C18-C17 118.0(2) 
O4-C25-C26 110.73(14) C27-C26-C31 118.0(2) C27-C26-C25 119.5(2) 
C31-C26-C25 122.4(2) C28-C27-C26 120.7(2) C29-C28-C27 121.2(2) 
C28-C29-C30 118.1(2) C28-C29-C32 122.1(2) C30-C29-C32 119.7(2) 
C31-C30-C29 120.8(2) C30-C31-C26 121.1(2) N1-C32-C29 108.93(14) 
C34-C33-C19 113.77(14) C35-C34-C39 118.8(2) C35-C34-C33 123.6(2) 
C39-C34-C33 117.6(2) C34-C35-C36 118.5(2) C34-C35-C1 123.6(2) 
C36-C35-C1 117.9(2) C37-C36-C35 122.6(2) O6-C37-C36 125.1(2) 
O6-C37-C38 116.3(2) C36-C37-C38 118.5(2) C39-C38-O5 124.3(2) 
C39-C38-C37 119.2(2) O5-C38-C37 116.5(2) C38-C39-C34 122.2(2) 
O6-C41-C42 110.92(14) C47-C42-C43 117.8(2) C47-C42-C41 120.3(2) 
C43-C42-C41 121.8(2) C44-C43-C42 121.0(2) C43-C44-C45 120.8(2) 
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C46-C45-C44 118.3(2) C46-C45-C48 122.7(2) C44-C45-C48 118.7(2) 
C45-C46-C47 120.8(2) C46-C47-C42 121.2(2) N1-C48-C45 109.15(14) 
C16-N1-C48 113.96(14) C16-N1-C32 114.45(14) C48-N1-C32 114.84(14) 
C6-O1-C8 117.5(2) C5-O2-C9 115.31(13) C22-O3-C24 117.39(14) 
C21-O4-C25 118.46(13) C38-O5-C40 116.32(14) C37-O6-C41 118.26(13) 
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